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Purpose:  The purpose of the ACS/ASCO Breast Cancer Survivorship Care Guideline is to 
provide recommendations to assist primary care and other clinicians in the care of female adult 
survivors of breast cancer.  
Methods:  A systematic review of the literature was conducted using PubMed through April 
2015.  A multidisciplinary expert workgroup, with expertise in primary care, gynecology, surgical 
oncology, medical oncology, radiation oncology, and nursing was formed and tasked with 
drafting the Breast Cancer Survivorship Care Guideline. 
Results: A total of 1073 articles met inclusion criteria and after full text review, 237 were 
included as the evidence base. Patients should undergo regular surveillance for breast cancer 
recurrence, including evaluation with a cancer-related history and physical exam, and should be 
screened for new primary breast cancer. Data do not support performing routine laboratory tests 
or imaging tests in asymptomatic patients to evaluate for breast cancer recurrence. Primary 
care clinicians should counsel patients about the importance of maintaining a healthy lifestyle, 
monitor for post-treatment symptoms that can adversely affect quality of life, and monitor for 
adherence to endocrine therapy. Recommendations provided in this guideline are based on 
current evidence in the literature and expert consensus opinion. Most of the evidence is not 
sufficient to warrant a strong evidence-based recommendation.  
Recommendations:  Recommendations on surveillance for breast cancer recurrence, 
screening for second primary cancers, assessment and management of physical and 
psychosocial long-term and late effects of breast cancer and treatment, health promotion and 
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Breast cancer is the most common non-cutaneous malignancy for women, representing 
4 in 10 female cancer survivors in the U.S.1  Long-term survival is common after breast cancer 
treatment, with a 5-year survival rate of almost 90%2; thus addressing survivors’ unique post-
treatment needs is critical to providing quality health care3. 
Nearly a decade ago, two landmark publications from the Institute of Medicine (IOM) 
highlighted the importance of surveillance, health promotion, and assessing and managing the 
myriad of physical, psychological, spiritual, social and practical long-term and late effects faced 
by many cancer survivors after completing active treatment4, 5. Recent publications affirm the 
importance of addressing health, wellness and quality of life concerns of post-treatment cancer 
survivors 3, 6, 7. In recognition of the increasing need for information to support primary care 
clinicians who care for breast cancer survivors, this guideline was developed to provide 
recommendations to enhance the quality of clinical follow-up care for those who have completed 
initial treatment for female breast cancer (e.g., surgery, radiation, targeted therapy, and/or 
chemotherapy)8.  
While many evidence-based clinical guidelines exist for diagnosis and treatment, there 
are few evidence-based clinical care guidelines addressing life-long follow-up care for survivors 
by cancer type. The National Comprehensive Cancer Network (NCCN) developed consensus-
based guidelines for the treatment of patients with breast cancer9 which include information on 
recommended surveillance for cancer recurrence or new cancers. The NCCN also has 
symptom-specific survivorship care guidelines addressing anthracycline-induced cardiac 
toxicity, anxiety and depression, cognitive function, fatigue, pain, sexual function, sleep 
disorders, and healthy lifestyles10. In addition, the American Society of Clinical Oncology 
(ASCO) has guidelines for the follow-up and management of patients with breast cancer 11, 12 as 
well as symptom-based guidelines specific to fatigue13, chemotherapy-induced peripheral 
neuropathy14, and anxiety and depressive symptoms 15 ; ASCO is also developing guidelines on 
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the prevention and monitoring of cardiac dysfunction in survivors of adult cancers and on the 
management of chronic pain. In addition, ASCO has recently endorsed the ACS guideline on 
prostate cancer survivorship16. The ACS/ASCO Breast Cancer Survivorship Care Guideline 
builds upon prior guidelines by providing comprehensive, holistic recommendations specific to 
post-treatment breast cancer clinical care to help primary care clinicians better manage potential 
long-term and late-effects, and to provide timely and appropriate screening and surveillance to 
improve overall health and quality of life of breast cancer survivors.  
This year approximately 231,840 women will be newly diagnosed with breast cancer and 
an estimated 3.1 million breast cancer survivors are alive in the U.S17. The median age at 
diagnosis is 61 years with 43% over the age of 65, thus cancer survivorship must be managed 
in coordination with comorbidities associated with aging1. Approximately 61% will have localized 
disease where survival outcomes are highest (99% 5-year relative survival rates for localized 
stage breast cancer versus 25% 5-year relative survival rate for distant stage breast cancer)2.  
Breast cancer treatment depends on the stage at diagnosis, size and location of the 
tumor, and tumor characteristics. Those who are Stage II or III at diagnosis may have more 
involved cancer treatment, which can result in greater likelihood and severity of the impact of 
treatment. Treatment generally includes two key components – treatment of the breast and local 
lymph nodes with surgery either with or without radiation therapy (“local therapy”) and drug 
treatments for cancer cells that may have spread (“adjuvant systemic therapy”) outside the 
breast. Surgical treatment for breast cancer includes breast conserving surgery with radiation or 
mastectomy with or without radiation and with or without immediate/delayed reconstruction. In 
women with a very high risk of contralateral cancer from inherited susceptibility (e.g., patients 
with mutations in BRCA1/2), contralateral prophylactic mastectomy may be performed 18, 19. 
Systemic therapy may precede (“neoadjuvant”) or follow (“adjuvant”) local therapy, and consists 
of combinations of hormonal therapy, chemotherapy and biological agents.  
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There is no standardized follow-up model for early stage breast cancer patients who 
have completed surgery, chemotherapy and radiation. Most of these women will have endocrine 
responsive tumors and will require endocrine therapy for a total of 5 to 10 years. Randomized 
trials have shown equivalent outcomes with follow-up by either the oncologist or a primary care 
physician20. Shared follow-up care between one or more oncologists and the primary physician 
is an additional possibility. However, the great majority of these patients will eventually be 
discharged back to their primary clinician for ongoing follow-up. It should be noted that these 
patients remain at risk indefinitely for complications of their previous cancer treatment.  Most 
also remain at risk indefinitely for local and/or systemic recurrence of their breast cancer. 
Gaps in post-treatment cancer survivorship resources and clinical follow-up care were 
identified through the work of the National Cancer Survivorship Resource Center (The 
Survivorship Center; http://www.cancer.org/survivorshipcenter), a collaboration between the 
American Cancer Society (ACS), The George Washington University (GW) Cancer Institute, 
and the Centers for Disease Control and Prevention (CDC), and funded by a five-year 
cooperative agreement from the CDC. The overarching goals of The Survivorship Center are to 
improve individual-, system-, and policy-level post-treatment survivorship clinical care, to 
develop resources to help survivors achieve optimal health and quality of life (QoL), as well as 
to highlight the importance of post-treatment survivorship as a public health issue8. A strategic 
partnership with the American Society of Clinical Oncology (ASCO) was formed to optimize 
consistent, evidence-based recommendations for survivorship care in patients with breast 
cancer.  
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This clinical practice guideline addresses five key areas of breast cancer survivorship  
to provide recommendations on best practice in the management of adult women after breast 
cancer treatment, focusing on the role of primary care clinicians and other clinicians who care 
for post-treatment breast cancer survivors. The five areas covered include (1) surveillance for 
breast cancer recurrence, (2) screening for second primary cancers, (3) assessment and 
management of physical and psychosocial long-term and late effects of breast cancer and 
treatment, (4) health promotion, and (5) care coordination and practice implications. 
 
The Bottom Line 
 
Recommendations for the ACS/ASCO Breast Cancer Survivorship Care Guideline  
 
Target Population 
Female adult breast cancer survivors 
 
Target Audience 
Primary care providers, medical oncologists, radiation oncologists, and other clinicians caring for breast 
cancer survivors  
 
Methods: An Expert Panel was convened to develop clinical practice guideline recommendations 
based on a systematic review of the medical literature. 
 
ACS/ASCO Key Recommendations for Breast Cancer Survivorship Care: 
 
SURVEILLANCE FOR BREAST CANCER RECURRENCE  
History and Physical 
Recommendation 1.1: It is recommended that primary care clinicians (a) Should individualize clinical 
follow-up care provided to breast cancer survivors based on age, specific diagnosis and treatment 
protocol and as recommended by the treating oncology team (LOE=2A); (b) Should make sure the 
patient receives a detailed cancer-related history and physical examination every 3 to 6 months for the 
first 3 years after primary therapy, every 6 to 12 months for the next 2 years, and annually thereafter 
(LOE=2A).  
 
Screening the breast for local recurrence or a new primary breast cancer 
Recommendation 1.2: It is recommended that primary care clinicians (a) Should refer women who 
have received a unilateral mastectomy for annual mammography on the intact breast and for those 
with lumpectomies an annual mammography of both breasts (LOE=2A); (b) Should not refer for routine 
screening with MRI of the breast unless the patient meets high risk criteria for increased breast cancer 
surveillance as per ACS Guidelines21 (LOE=2A).  
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Laboratory Tests and Imaging 
Recommendation 1.3: It is recommended that primary care clinicians should not offer routine laboratory 
tests or imaging, except mammography if indicated, for the detection of disease recurrence in the 
absence of symptoms (LOE=2A).  
 
Signs of Recurrence 
Recommendation 1.4: It is recommended that primary care clinicians should educate and counsel all 
women about the signs and symptoms of local or regional recurrence (LOE=2A).  
 
Risk Evaluation and Genetic Counseling 
Recommendation 1.5: It is recommended that primary care clinicians (a) Should assess your patient’s 
cancer family history; (b) Should offer genetic counseling if potential hereditary risk factors are 
suspected (e.g., women with a strong family history of cancer [breast, colon, endometrial], or age 60 or 
younger with triple negative breast cancer)22 (LOE=2A). 
 
Endocrine Treatment Impacts, Symptom Management 
Recommendation 1.6: It is recommended that primary care clinicians should counsel patients to adhere 
to adjuvant endocrine (anti-estrogen) therapy (LOE=2A). 
 
SCREENING FOR SECOND PRIMARY CANCERS 
Cancer Screenings in the Average Risk Patient 
Recommendation 2.1: It is recommended that primary care clinicians (a) Should screen for other 
cancers as they would for patients in the general population. (b) Should provide an annual 
gynecological assessment for post-menopausal women on selective estrogen receptor modulator 
therapies (SERMs). 
 
ASSESSMENT AND MANAGEMENT OF PHYSICAL AND PSYCHOSOCIAL LONG-TERM AND LATE 
EFFECTS OF BREAST CANCER AND TREATMENT 
Body Image Concerns 
Recommendation 4.1: It is recommended that primary care clinicians (a) Should assess for patient 
body image/appearance concerns (LOE=0); (b) Should offer the option of adaptive devices (e.g. breast 




Recommendation 4.2: It is recommended that primary care clinicians (a) Should counsel survivors on 
how to prevent / reduce risk of lymphedema, including weight loss for those who are overweight or 
obese (LOE=0); (b) Should refer patients with clinical symptoms or swelling suggestive of lymphedema 
to a therapist knowledgeable about the diagnosis and treatment of lymphedema, such as a physical 
therapist, occupational therapist, or lymphedema specialist (LOE=0). 
 
Cardiotoxicity 
Recommendation 4.3: It is recommended that primary care clinicians (a) Should monitor lipid levels 
and provide cardiovascular monitoring, as indicated (LOE=0); (b) Should educate breast cancer 
survivors on healthy lifestyle modifications, potential cardiac risk factors, and when to report relevant 
symptoms (shortness of breath or fatigue) to their health care provider (LOE=I).  
 
Cognitive Impairment 
Recommendation 4.4: It is recommended that primary care clinicians (a) Should ask patients if they are 
experiencing cognitive difficulties (LOE=0); (b) Should assess for reversible contributing factors of 
cognitive impairment and optimally treat when possible (LOE=IA); (c) Should refer patients with signs 
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of cognitive impairment for neurocognitive assessment and rehabilitation, including group cognitive 
training if available (LOE=IA). 
 
Distress, Depression, Anxiety 
Recommendation 4.5: It is recommended that primary care clinicians (a) Should assess patients for 
distress, depression, and/or anxiety (LOE=I); (b) Should conduct a more probing assessment for 
patients at a higher risk of depression (e.g., young patients, those with a history of prior psychiatric 
disease, and patients with low socioeconomic status) (LOE=III); (c) Should offer in-office counseling 
and/or pharmacotherapy and/or refer to appropriate psycho-oncology and mental health resources as 
clinically indicated if signs of distress, depression, or anxiety are present (LOE=I).   
 
Fatigue 
Recommendation 4.6: It is recommended that primary care clinicians (a) Should assess for fatigue and 
treat any causative factors for fatigue, including anemia, thyroid dysfunction, and cardiac dysfunction 
(LOE= 0); (b) Should offer treatment or referral for factors that may impact fatigue (e.g. mood 
disorders, sleep disturbance, pain, etc.) for those who do not have an otherwise identifiable cause of 
fatigue (LOE= I); (c) Should counsel patients to engage in regular physical activity and refer for 
cognitive behavioral therapy as appropriate (LOE= I).  
 
Bone Health 
Recommendation 4.7: It is recommended that primary care clinicians (a) Should refer post-menopausal 
breast cancer survivors for a baseline DEXA scan (LOE=0); (b) Should refer for repeat DEXA scans 
every 2 years for women taking an aromatase inhibitor, premenopausal women taking tamoxifen 
and/or a GnRH agonist, and women who have chemo-induced premature menopause (LOE=0).  
 
Musculoskeletal Health 
Recommendation 4.8: It is recommended that primary care clinicians (a) Should assess for 
musculoskeletal symptoms, including pain, by asking patients about their symptoms at each clinical 
encounter (LOE=0); (b) Should offer one or more of the following interventions based on clinical 
indication: acupuncture, physical activity, referral for physical therapy or rehabilitation (LOE=III).  
 
Pain and Neuropathy 
Recommendation 4.9: It is recommended that primary care clinicians (a) Should assess for pain and 
contributing factors for pain with the  use of a simple pain scale and comprehensive history of the 
patient’s complaint (LOE=0); (b) Should offer interventions, such as acetaminophen, nonsteroidal anti-
inflammatory drugs, physical activity and/or acupuncture, for pain (LOE=I); (c) Should refer to an 
appropriate specialist depending on the etiology of the pain once the underlying etiology has been 
determined (e.g., lymphedema specialist, occupational therapist, etc.) (LOE=0); (d) Should assess for 
peripheral neuropathy and contributing factors for peripheral neuropathy by asking the patient about 
their symptoms, specifically numbness and tingling in their hands and/or feet, and the characteristics of 
that symptom (LOE=0); (e) Should offer physical activity for neuropathy; (f) Should offer duloxetine for 
patients with neuropathic pain, numbness and tingling (LOE=IB).  
 
Infertility 
Recommendation 4.10: It is recommended that primary care clinicians should refer survivors of 
childbearing age who experience infertility to a specialist in reproductive endocrinology and infertility as 
soon as possible (LOE=0). 
 
Sexual Health 
Recommendation 4.11: It is recommended that primary care clinicians (a) Should assess for signs and 
symptoms of sexual dysfunction or problems with sexual intimacy (LOE=0); (b) Should assess for 
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reversible contributing factors to sexual dysfunction and treat, when appropriate (LOE=0); (c) Should 
offer nonhormonal, water-based lubricants and moisturizers for vaginal dryness (LOE=IA); (d) Should 
refer for psychoeducational support, group therapy, sexual counseling, marital counseling or intensive 
psychotherapy, when appropriate (LOE=IA). 
 
Premature Menopause/Hot Flashes 
Recommendation 4.12: It is recommended that primary care clinicians should offer selective serotonin-
norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), 
gabapentin, lifestyle modifications and/or environmental modifications to help mitigate vasomotor 




Recommendation 5.1: It is recommended that primary care clinicians (a) Should assess the information 
needs of the patient related to breast cancer and its treatment, side effects, other health concerns, and 
available support services (LOE=0); (b) Should provide or refer survivors to appropriate resources to 
meet these needs (LOE=0). 
 
Obesity 
Recommendation 5.2: It is recommended that primary care clinicians (a) Should counsel survivors to 
achieve and maintain a healthy weight (LOE=III); (b) Should counsel survivors if overweight or obese 
to limit consumption of high-calorie foods and beverages and increase physical activity to promote and 
maintain weight loss (LOE=IA, III).  
 
Physical Activity 
Recommendation 5.3: It is recommended that primary care clinicians should counsel survivors to 
engage in regular physical activity consistent with the ACS guideline23 and specifically: (a) Should 
avoid inactivity and return to normal daily activities as soon as possible following diagnosis (LOE=III); 
(b) Should aim for at least 150 minutes of moderate or 75 minutes of vigorous aerobic exercise per 
week (LOE=I, IA); (c) Should include strength training exercises at least 2 days per week. Emphasize 
strength training for women treated with adjuvant chemotherapy or hormone therapy (LOE= IA).  
 
Nutrition 
Recommendation 5.4: It is recommended that primary care clinicians should counsel survivors to 
achieve a dietary pattern that is high in vegetables, fruits, whole grains, and legumes, low in saturated 
fats, and limited in alcohol consumption (LOE= IA, III). 
 
Smoking Cessation 
Recommendation 5.5: It is recommended that primary care clinicians should counsel survivors to avoid 
smoking and refer survivors who smoke to cessation counseling and resources (LOE= I).  
 
CARE COORDINATION / PRACTICE IMPLICATIONS 
Survivorship Care Plan 
Recommendation 6.1: It is recommended that primary care clinicians should consult with the cancer 
treatment team and obtain a treatment summary and Survivorship Care Plan (LOE=0, III).  
 
Communication with Oncology Team 
Recommendation 6.2: It is recommended that primary care clinicians should maintain communication 
with the oncology team throughout your patient’s diagnosis, treatment and post-treatment care to 
ensure care is evidence-based and well-coordinated (LOE=0). 
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Inclusion of Family 
Recommendation 6.3 It is recommended that primary care clinicians should encourage the inclusion of 
caregivers, spouses, or partners in usual breast cancer survivorship care and support (LOE=0).   
 
Additional Resources: More information, including a Data Supplement with additional evidence 
tables, is available at www.asco.org/guidelines/xxx and www.asco.org/guidelineswiki. Patient 
information is available at www.cancer.net.  
 
METHODS 
Methods used to develop this guideline reflect an evolving process that was influenced 
by ACS screening24 and survivorship16 guidelines. Where appropriate, this guideline builds upon 
the recently published ASCO symptom-based guidelines for adult cancer survivors 14, 15, 25. 
 
Panel Formation 
A multidisciplinary expert workgroup was formed and tasked with drafting the Breast 
Cancer Survivorship Care Guideline. Workgroup members had expertise in primary care, 
gynecology, surgical oncology, medical oncology, radiation oncology, and nursing. In addition a 
cancer survivor was included to provide a patient perspective. 
 
Literature Review 
The literature review began with an environmental scan of existing guidelines and 
guidance developed by other organizations [e.g., NCCN9, 26, 27; ASCO 11, 14, 15, 25, 28; Long-term 
Follow-up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers of the 
Children’s Oncology Group (http://survivorshipguidelines.org)], specific medical centers (e.g., 
The University of Texas MD Anderson Clinical Tools and Resources Breast Cancer 
Survivorship algorithm 29, US Preventive Services Task Force22, 30, 31, the American Association 
of Clinical Endocrinologists32, individual publications33-36, available from other countries (e.g., 
Australian Cancer Survivorship Centre), and from other expert panels (e.g., Breast Health 
Global Initiative guidelines37). 
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Literature Search Strategy 
A systematic review of the literature was conducted using PubMed through April 2015. 
Studies on childhood cancers, qualitative studies, and non-English publications were excluded. 
Search terms included: cancer survivor AND review OR meta-analysis OR systematic review 
OR guidelines; guidance AND breast cancer OR breast cancer survivor; breast cancer patient 
post-treatment AND symptom management OR late effects OR long-term effects OR 
psychosocial care OR palliative care OR health promotion OR surveillance OR screening for 
new cancers OR self-management OR guidelines OR guidance OR follow up OR follow-up OR 
side effects OR (chemotherapy AND side effects) OR (radiation AND side effects), OR surgery 
OR treatment complications OR genetic counseling and testing OR survivor or patient 
interventions OR provider interventions OR provider education OR barriers. Additional search 
attempts included breast cancer OR breast cancer survivor OR breast cancer patient post-
treatment AND (symptom-specific terms, such as lymphedema, body image, early menopause, 
etc).  
The highest priority was given to articles that met the following criteria: peer reviewed 
publication in English since 2004, unless a seminal article published before that date still carried 
the most weight, including randomized controlled trials (RCTs), prospective cohort studies, and 
well-conducted, population-based, case-control studies; large studies of more than 100 cancer 
cases analyzed and with high-quality assessment of covariates, and analytic methods; and 
analyses controlled for important confounders (e.g., pre-existing comorbid conditions). 
Level of Evidence 
(LOE) 
 
I Meta analyses of RCTs  
IA RCT of breast cancer survivors 
IB RCT based on cancer survivors across multiple cancer sites 
IC RCT not based on cancer survivors, but on general population 
experiencing a specific long-term or late effect (e.g., managing 
menopausal symptoms, sexual dysfunction, etc.) 
IIA Non-randomized clinical trials based on breast cancer survivors 
IIB Non-randomized clinical trials based on cancer survivors across multiple 
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IIC Non-randomized clinical trials not based on cancer survivors, but on 
general population experiencing a specific long-term or late effect 
III Case-control study or prospective cohort study 
0 Expert opinion, observational study (excluding case-control and 
prospective cohort studies), clinical practice, literature review, or pilot 
study 
2A NCCN guideline 
 
Workgroup members were also asked to consider the specific level of evidence criteria 
along with consistency across studies and study designs; dose-response when presenting 
treatment impacts; race / ethnicity differences; and second primary cancers for which survivors 
are at high risk due to treatment and genetic considerations. After finalization by the workgroup, 
the guideline manuscript was sent to additional internal and external experts for review and 
comment prior to submission for publication. The manuscript summarizes literature with the 
highest level of evidence (i.e., RCTs). A comprehensive list of evidence is available in the 
Appendix.   
 This is the most recent information as of the publication date. For updates, the most 
recent information, and to submit new evidence, please visit www.asco.org/guidelines/xxx and 
the ASCO Guidelines Wiki (www.asco.org/guidelineswiki).  Based on formal review of the 
emerging literature, ACS/ASCO will determine the need to update on a regular basis.  At 
minimum, it will be updated every 5 years.   
 
Guideline Disclaimer  
 The Clinical Practice Guidelines and other guidance published herein are provided by 
ACS and ASCO to assist providers in clinical decision making. The information herein should 
not be relied upon as being complete or accurate, nor should it be considered as inclusive of all 
proper treatments or methods of care or as a statement of the standard of care. With the rapid 
development of scientific knowledge, new evidence may emerge between the time information 
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is developed and when it is published or read. The information is not continually updated and 
may not reflect the most recent evidence. The information addresses only the topics specifically 
identified therein and is not applicable to other interventions, diseases, or stages of diseases. 
This information does not mandate any particular course of medical care. Further, the 
information is not intended to substitute for the independent professional judgment of the 
treating provider, as the information does not account for individual variation among patients. 
Recommendations reflect high, moderate, or low confidence that the recommendation reflects 
the net effect of a given course of action. The use of words like “must,” “must not,” “should,” and 
“should not” indicates that a course of action is recommended or not recommended for either 
most or many patients, but there is latitude for the treating physician to select other courses of 
action in individual cases. In all cases, the selected course of action should be considered by 
the treating provider in the context of treating the individual patient. Use of the information is 
voluntary. ACS and ASCO provide this information on an “as is” basis and make no warranty, 
express or implied, regarding the information. ACS and ASCO specifically disclaim any 
warranties of merchantability or fitness for a particular use or purpose. ACS and ASCO assume 
no responsibility for any injury or damage to persons or property arising out of or related to any 
use of this information, or for any errors or omissions. 
 
Guideline and Conflicts of Interest 
The Expert Panel was assembled in accordance with ACS’s Conflict of Interest Procedures and 
ASCO’s Conflict of Interest Management Procedures for Clinical Practice Guidelines 
(“Procedures,” summarized at http://www.asco.org/rwc). Members of the Panel completed 
ACS’s Guidelines Development Participant Disclosure Form, ASCO’s disclosure form, and the 
International Committee of Medical Journal Editors (ICMJE) Form for Disclosure of Potential 
Conflicts of Interest, which requires disclosure of financial and other interests that are relevant 
to the subject matter of the guideline, including relationships with commercial entities that are 
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reasonably likely to experience direct regulatory or commercial impact as a result of 
promulgation of the guideline. Categories for disclosure include employment; leadership; stock 
or other ownership; honoraria, consulting or advisory role; speaker's bureau; research funding; 
patents, royalties, other intellectual property; expert testimony; travel, accommodations, 
expenses; and other relationships. In accordance with the Procedures, the majority of the 
members of the Panel did not disclose any such relationships. 
 
RESULTS 
A total of 1073 articles (list is available as a supplement to this manuscript) met inclusion criteria 
and after full text review, 237 were included as the evidence base. Only 2% of eligible articles 
were rated as Level I evidence, 7% were Level IA, and 2% were Level IIA. The majority of 
evidence was rated as Level III (26%) and Level 0 (64%). Recommendations provided in this 
guideline are based on current evidence in the literature and expert consensus opinion.  Most of 
the evidence is not sufficient to warrant a strong evidence-based recommendation. Rather, 
recommendations should be largely viewed as possible management strategies given the 




SURVEILLANCE FOR BREAST CANCER RECURRENCE  
(Table 1: Guideline for Surveillance for Breast Cancer Recurrence and Genetic Counseling) 
Genetic Testing / Counseling 
The guiding principle of surveillance is that it should consider a patient’s risk of 
recurrence, in the context of functional status and patient preferences. In asymptomatic 
patients, routine screening tests to detect recurrence are not recommended.  However, a careful 
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history is often needed to assure that patients are indeed asymptomatic. Patients at a higher 
risk for local recurrence should have appropriate screening.  
 History and Physical 
Recommendation 1.1: It is recommended that primary care clinicians (a) Should 
individualize clinical follow-up care provided to breast cancer survivors based on age, 
specific diagnosis and treatment protocol as recommended by the treating oncology 
team (LOE=2A); (b) Should make sure the patient receives a detailed cancer-related 
history and physical examination every 3 to 6 months for the first 3 years after primary 
therapy, every 6 to 12 months for the next 2 years, and annually thereafter by the treating 
oncology team (LOE=2A).  
Clinical interpretation: Perform periodic history and physical examination on all breast cancer 
survivors. In a previous ASCO guideline, ASCO recommended that all female breast cancer 
survivors have a detailed history and physical examination every 3 to 6 months for the first 3 
years after primary therapy, every 6 to 12 months for the next 2 years, and annually thereafter in 
order to detect cancer recurrence at an early stage 11, 12. Frequency should be determined by 
the treating oncologist and be based on the individual risk profile and perspective of the patient. 
This can be done in collaboration with the primary care clinician. Patients should be made 
aware of the signs and symptoms of disease recurrence and be instructed to seek medical 
attention if any of the signs or symptoms occur between scheduled follow-up visits. If one or 
more additional oncology health care providers are following the patient, the frequency of the 
primary physician’s visits should be adjusted accordingly.  Clinicians can recommend 
vaccinations to their patients with a breast cancer history as appropriate based on guidelines; 
they can receive flu (shot, not nasal) or pneumonia vaccine at any time, including during 
chemotherapy, and zoster vaccine when not receiving chemotherapy 38. 
Screening the Breast for Local Recurrence or a New Primary Breast Cancer 
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Recommendation 1.2: It is recommended that primary care clinicians (a) Should refer 
women who have received a unilateral mastectomy for annual mammography on the 
intact breast and for those with lumpectomies an annual mammography of both breasts 
(LOE=2A); (b) Should not refer for routine screening with MRI of the breast unless the 
patient meets high risk criteria for increased breast cancer surveillance as per ACS 
Guidelines21 (LOE=2A).  
Clinical interpretation: Mammography should be performed yearly on the breast treated by 
breast conserving surgery and on the intact contralateral breast. More frequent mammography 
is only warranted for evaluation or follow-up of a suspicious finding 11. Following mastectomy, 
the site of the reconstructed breast does not require imaging. While MRI of the breast is more 
sensitive than mammography, there is an increased risk of false positive findings that may lead 
to unnecessary additional imaging and often unnecessary biopsies. Use of MRI can only be 
justified if the probability of missing a cancer with mammography alone is sufficiently high. In 
women who have not undergone bilateral mastectomy, the use of MRI of the breasts in 
screening for local recurrence or a new primary cancer should be restricted to women who meet 
the high risk criteria by the ACS or ASCO 11, 21, 39.  High risk is defined as a woman with a 
lifetime risk of a second primary breast cancer  > 20%, such as a woman with a BRCA1/2 
mutation or a very strong family history of breast cancer21.  
 
Laboratory Tests and Imaging 
Recommendation 1.3: It is recommended that primary care clinicians should not offer 
routine laboratory tests or imaging, except mammography if indicated, for the detection 
of disease recurrence in the absence of symptoms (LOE=2A).  
Clinical interpretation: Consistent with ASCO and NCCN guidelines, routine testing with breast 
cancer tumor markers or imaging studies (e.g., bone scan, chest x-ray, PET-CT scans, MRI 
scans, biomarkers) should not be performed for screening purposes because they have not 
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been shown to improve survival outcomes or quality of life in asymptomatic patients 9, 11. Chest 
x-rays and advanced body imaging (i.e., CT, MRI, PET-CT, bone scan) should be ordered only 
if disease recurrence is suspected 40. Randomized trials in the 1980s comparing clinical follow-
up to periodic advanced imaging did not demonstrate a survival advantage with advanced 
imaging, and did show a significant rate of false-positive findings with additional testing41-43.  
 
Signs of Recurrence 
Recommendation 1.4: It is recommended that primary care clinicians should educate and 
counsel all women about the signs and symptoms of local or regional recurrence 
(LOE=2A).  
Clinical interpretation: Physicians should educate and counsel patients about the signs and 
symptoms of local or regional recurrence including new lumps (e.g., in underarm or neck), rash 
or skin changes on the breast or chest wall, chest pain, changes in the contour/shape/size of 
the breast, and swelling of the breast or arm 11. Evaluation of patient-reported symptoms is 
essential in detecting a recurrence as early as possible which may impact survival. 
 
Risk Evaluation and Genetic Counseling 
Recommendation 1.5: It is recommended that primary care clinicians (a) Should assess 
your patient’s cancer family history; (b) Should offer genetic counseling if potential 
hereditary risk factors are suspected (e.g., women with a strong family history of cancer 
[breast, colon, endometrial], or age 60 or younger with triple negative breast cancer)22 
(LOE=2A). 
Clinical interpretation: To identify those women with breast cancer who have a high risk of a 
second primary breast cancer and / or may have a genetic susceptibility to cancer that may 
affect other family members, a detailed history including key risk factors and paternal and 
maternal family history should be obtained for all patients. Those with a family history of breast 
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or ovarian cancer or with cancer in a certain age group and / or cancer type should be referred 
for genetic counseling for consideration of testing for hereditary predisposition to genetic 
mutations. Specifically, genetic counseling for consideration of testing for hereditary 
predisposition to gene mutations should be recommended for breast cancer survivors: with at 
least one grandparent of Ashkenazi Jewish heritage; younger than 50 years of age at diagnosis; 
with a history of ovarian cancer at any age or in any first- or second-degree relative; with a first-
degree relative with breast cancer diagnosed before the age of 50; with two or more first- or 
second-degree relatives diagnosed with breast cancer at any age; with a diagnosis of bilateral 
breast cancer; with a history of breast cancer in a male relative; or any survivor diagnosed at 
age 60 or younger with triple negative breast cancer22. It is important to periodically review 
these issues with the patient as some survivors may not have been offered genetic counseling 
or testing at the time of diagnosis and/or new cancer events may have occurred in the family 
after the initial diagnosis and treatment. Because new primary cancers may be associated with 
some hereditary syndromes, identifying the risk of genetic mutations in the survivor may help to 
formulate a prevention strategy to reduce the risk of a new cancer. In addition, this information 
could be helpful to family members as well. 
 Genetic testing should be preceded by consultation with a genetics counselor or other 
trained professional to assure full discussion of the risks and benefits, and to assure that other 
genetic syndromes beyond BRCA1 and BRCA2 breast / ovarian syndromes are considered. 
Depending on the hereditary gene that is identified, different screening and prevention 
strategies may be offered. Recommendations for alternate screening and prevention strategies 
depend on the specific genetic syndrome, and should be left to a trained professional in 
coordination with the oncology team and primary care clinician.    
 
Endocrine Treatment Impacts, Symptom Management 
Page 18 of 87CA: A Cancer Journal for Clinicians













Recommendation 1.6: It is recommended that primary care clinicians should counsel 
patients to adhere to adjuvant endocrine (anti-estrogen) therapy (LOE=2A).  
Clinical interpretation: Endocrine therapy (tamoxifen, aromatase inhibitors, or ovarian 
suppression therapy) used as adjuvant systemic therapy for 5-10 years reduces the risk of 
recurrence and of subsequent second primary breast cancers and improves overall survival. 
Adherence to endocrine therapy is necessary to achieve its survival benefits. Unfortunately 
some women discontinue endocrine therapy because of cost, side effects and other reasons. 
Reported adherence for a 5 year course of therapy ranges from 50 to 92% of breast cancer 
patients44. Primary care clinicians should assess and encourage adherence to adjuvant 
endocrine therapy at each visit9.  
 
SCREENING FOR SECOND PRIMARY CANCERS 




Cancer Screenings in the Average Risk Patient 
Recommendation 2.1: It is recommended that primary care clinicians (a) Should screen 
for other cancers as they would for patients in the general population; (b) Should provide 
an annual gynecological assessment for post-menopausal women on selective estrogen 
receptor modulator therapies (SERMs).45 
Clinical interpretation: Women should be advised to follow the ACS screening and early 
detection guidelines for cervical, colorectal, endometrial, and lung cancers detailed in Table 245. 
Post-menopausal women taking SERMs, such as tamoxifen or raloxifene, should be advised to 
report any vaginal spotting or bleeding as these drugs slightly increase the risk of endometrial 
cancer in post-menopausal women. In the absence of abnormal vaginal spotting or bleeding, 
periodic imaging is not of value and may lead to unwarranted biopsies46. Discuss the risks, 
benefits, and limitations of screening modalities with your patients. 
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ASSESSMENT AND MANAGEMENT OF PHYSICAL AND PSYCHOSOCIAL LONG-TERM 
AND LATE EFFECTS OF BREAST CANCER AND TREATMENT 
The risk of physical long-term and late effects following therapy for breast cancer is 
associated with several factors, including: a) type of treatment, b) duration and dose of 
treatment(s) (increasing cumulative dose and duration of therapy increases the potential risk), c) 
specific type of chemotherapy, d) receipt of and type of hormone treatment, and e) age of 
patient during treatment. Modalities of treatment include surgery, radiation therapy, 
chemotherapy, targeted therapy, and/or endocrine therapy. Primary care clinicians should refer 
to the patient’s cancer treatment summary, if available, for specific drugs and doses (see 
Recommendation 6.1). Table 3 lists potential physical and psychosocial long-term and late 
effects associated with surgery, radiation, chemotherapy, hormone therapy and targeted 
treatment. Long-term effects are medical problems that develop during active treatment and 
persist after the completion of treatment; whereas, late effects are medical problems that 
develop or become apparent months or years after treatment is completed. Recommendations 
for the assessment and management of specific physical and psychosocial long-term and late 
effects most commonly experienced by breast cancer survivors are detailed in Table 4.   
Table 4: Guidelines for Assessment and Management of Physical and Psychosocial Long-term / 
Late Effects 
 
Body Image Concerns 
Recommendation 4.1: It is recommended that primary care clinicians (a) Should assess 
for patient body image/appearance concerns (LOE=0); (b) Should offer the option of 
adaptive devices (e.g., breast prostheses, wigs) and/or surgery when appropriate (LOE: 
0); (c) Should refer for psychosocial care as indicated (LOE=IA). 
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Clinical interpretation:  Body image / appearance changes can be a major area of concern 
affecting 31-67% of breast cancer survivors 47.  Factors such as the loss of a breast, scarring 
and / or lymphedema following surgery, hair loss or sexual dysfunction /chemotherapy-related 
early menopause, skin changes from radiation, and weight gain can all lead to changes in body 
image with negative implications on short and long term QoL48. These body image implications 
are especially relevant for young breast cancer survivors49-51. Among female breast cancer 
survivors who are sexually active, greater body image problems have been found to be 
associated with mastectomy with or without reconstruction, hair loss from chemotherapy, 
concern with weight change, decreased self-esteem prior to the time of cancer diagnosis, 
poorer mental health, and a partner's difficulty understanding one's feelings50.  
Patients with radiation-associated breast/soft-tissue fibrosis should be considered for 
therapy with oral pentoxifylline (trental) and vitamin E52-55. A radiation oncologist should evaluate 
such patients to assure that the clinical findings are consistent with the radiation treatment 
delivered.  Recurrent cancer or infection can sometimes be mistaken for radiation-associated 
fibrosis. Primary care clinicians should refer back to the oncologist (medical, surgical, or 
radiation) if they ever are uncertain about potential recurrence. 
Breast reconstructive surgery should be considered in women who do not feel 
comfortable with the results of their initial breast surgery, whether lumpectomy or mastectomy, 
as there may be ways to improve symmetry or appearance.  Breast forms/prostheses or bras 
are options that are available to survivors who have undergone mastectomy or non-breast 
conserving therapies, and generally require a prescription from a physician.  Special lingerie, 
attachable nipples, and other resources can help the survivor regain self-esteem. Most 
insurance plans cover mastectomy prostheses and specialty bras. In addition, wigs, hats, 
scarves and other accessories are available for survivors who experience permanent hair loss 
(alopecia is a rare complication of chemotherapy), color or texture change. Women should 
check with their insurance company and obtain a prescription from their physicians. Breast 
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cancer care centers or specialists often maintain directories of resources in their community 
where patients can find these products. 
Primary care clinicians should refer patients having body image concerns that are not 
corrected by above options for psychosocial care. For example, for women who experience 
early menopause or for those with sexual concerns, support groups, psychotherapy, cognitive 
behavioral therapy, couple-based interventions or sex therapy may be helpful. Couple-based 




Recommendation 4.2: It is recommended that primary care clinicians (a) Should counsel 
survivors on how to prevent / reduce risk of lymphedema, including weight loss for those 
who are overweight or obese (LOE=0); (b) Should refer patients with clinical symptoms 
or swelling suggestive of lymphedema to a therapist knowledgeable about the diagnosis 
and treatment of lymphedema, such as a physical therapist, occupational therapist, or 
lymphedema specialist (LOE=0). 
Clinical interpretation: All breast cancer survivors who undergo breast surgery and / or radiation 
are at risk for lymphedema. This is arm, breast, or chest wall swelling as a result of a blockage 
of the lymphatic fluid from the arm and / or breast leading to retention of fluid and swelling. The 
incidence of lymphedema among breast cancer survivors varies widely57 though it is estimated 
that over 40% of survivors will experience lymphedema to some degree58, 59. The risk of 
lymphedema is much lower with sentinel lymph node dissections than with the full axillary lymph 
node dissection previously performed in all cases60. Lymphedema may occur immediately after 
treatment or develop after many years. Radiation treatment may cause or exacerbate 
lymphedema, especially radiation to the supraclavicular nodes or  axilla61.  
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The degree of swelling associated with lymphedema varies widely even for those 
receiving similar surgery and /or radiation. In most cases, it is generally limited in extent and is 
not disabling. In some cases the swelling is extensive and leads to significant disability such as 
limitation of the ability to perform fine motor functions with the hand as well as limited range of 
motion of other affected joints62. In addition, the swelling may cause symptoms ranging from 
mild discomfort to overt pain. The swelling may be of a noticeable degree and make clothes 
difficult to fit, and cause pain from the added weight of the arm. The International Society of 
Lymphedema provides a staging system to categorize the extent of lymphedema63. Patients 
with lymphedema are also at greater risk for the development of cellulitis of the breast, arm or 
chest which, especially if not promptly treated with antibiotics, may exacerbate lymphedema.             
More studies are needed in the area of lymphedema prevention above and beyond 
biopsy types and surgical strategies (sentinel lymph node dissections and axillary reverse 
mapping)64. Obesity is also a risk factor for lymphedema65, 66 so physicians should recommend 
weight loss for those who are overweight or obese and the importance of maintaining a normal 
weight (see also Recommendation 5.2). Historically patients with axillary 
lymphadenectomies/radiation have been advised to avoid physical activity and heavy lifting with 
the arm on the affected side. However, one study has shown that supervised slowly progressive 
resistance training is safe and effective for breast cancer survivors with regards to lymphedema 
development. Further, this type of physical activity may reduce the likelihood of arm swelling 
among breast cancer survivors at high risk for lymphedema due to having 5 or more nodes 
removed and in improving the symptoms and severity for those in whom the condition was 
already present67. While the results of this study suggest a promising intervention for 
lymphedema, additional research is warranted. 
Therefore, primary care clinicians should focus on the early identification and management of 
lymphedema among their patients with breast cancer68.  
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Patients who develop clinical symptoms or swelling suggestive of lymphedema should 
be referred to a therapist knowledgeable about the diagnosis and treatment of lymphedema. 
Depending on available resources in a community, this may be a physical69 or occupational70 
therapist or a specialist therapist trained in lymphedema management.  
 
Cardiotoxicity 
Recommendation 4.3: It is recommended that primary care clinicians (a) Should 
monitor lipid levels and provide cardiovascular monitoring, as indicated (LOE=0); (b) 
Should educate breast cancer survivors on healthy lifestyle modifications, potential 
cardiac risk factors, and when to report relevant symptoms (shortness of breath or 
fatigue) to their health care provider (LOE=I).  
Clinical interpretation: Radiation, chemotherapy and hormonal/endocrine therapy with 
aromatase inhibitors have been associated with an increased risk of cardiovascular disease in 
patients with breast cancer71, 72. The risk of heart disease increases in post-menopausal women, 
as endogenous estrogens in younger women contribute to the low prevalence of cardiovascular 
disease in that population. Breast cancer patients who experience treatment-related early 
menopause may therefore be at higher risk for heart disease than age-matched women in the 
general population. The chemotherapeutic agents epirubicin and doxorubicin are associated 
with a low but real risk of cardiomyopathy73; similarly, trastuzumab is associated with an 
increased risk of cardiac dysfunction, most notably when given concomitantly or after an 
anthracycline, as  has been detailed by the European Society for Medical Oncology74. 
Aromatase inhibitors can raise cholesterol levels75, 76 and the risk of diabetes. Significant weight 
gain may lead to hypertension and insulin resistance which further elevate risk of cardiovascular 
disease. Primary care clinicians should monitor lipid levels and engage in cardiovascular 
monitoring consistent with clinical standards for other high risk populations (e.g., US Preventive 
Services Task Force recommendations30). 
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It is important to educate breast cancer survivors about lifestyle modifications, including 
smoking cessation, diet and exercise (see Recommendations 5.3-5.5) that may reduce risk or 
severity of cardiotoxicity or cardiovascular diseases generally. Patients should be advised to be 
aware of the potential risk for cardiotoxicities and report symptoms such as shortness of breath 
or fatigue (without an otherwise identifiable cause) to their health care provider. However routine 
screening or testing for cardiovascular disease in asymptomatic patients beyond careful history 
and physical examination are not warranted.    
ASCO is currently developing a guideline on the prevention and monitoring of cardiac 
dysfunction in survivors of adult cancers. 
 
Cognitive Impairment 
Recommendation 4.4: It is recommended that primary care clinicians (a) Should ask 
patients if they are experiencing cognitive difficulties (LOE=0); (b) Should assess for 
reversible contributing factors of cognitive impairment and optimally treat when possible 
(LOE=IA); (c) Should refer patients with signs of cognitive impairment for neurocognitive 
assessment and rehabilitation, including group cognitive training if available (LOE=IA). 
Clinical interpretation: Impairment in cognitive function as a result of cancer and its treatment 
can lead to distress and impaired quality of life in breast cancer survivors. Up to 75% of breast 
cancer patients in treatment and 35% following treatment report cognitive impairment, including 
problems with concentration, executive function, and memory77-79. Cognitive impairment can 
also have detrimental effects on the survivor’s role within the family, workplace, and in society80, 
81.  Clinicians should ask patients if they are having cognitive difficulties and listen to family 
members’ reporting of patient cognitive symptoms. If this is an issue, consultation with a 
neuropsychologist for assessment and referral for cognitive rehabilitation strategies should be 
offered as one would do with the general population.  
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The causes of cognitive impairment are thought to be multifactorial and may include 
treatable conditions, such as fatigue, insomnia, and depression. Links have been suggested 
between cognitive impairment and adjuvant chemotherapy82-84; surgery / anesthesia85; 
endocrine therapy77, 86; as well as cancer itself77.  Research suggests that older adults and / or 
those with lower cognitive reserves may be more susceptible to cognitive impairment from 
treatment87 and that there may also be genetic factors associated with certain estrogen 
metabolism genes88, 89.   
 The treatment of cognitive impairment in the breast cancer survivor is not well 
established. A few studies have shown some success with pharmaceuticals, such as 
modafinil90, that have helped improve cognitive impairment, but the data are not consistent91. 
Cognitive rehabilitation strategies including the practice of group cognitive training (i.e., 
interventions geared towards improving, restoring or maintaining mental function through 
structured, repetitive practice of tasks posing a mental challenge or requiring the person to 
problem solve) has been found to be helpful at reducing cognitive impairment in breast cancer 
survivors92,93. Primary care clinicians should provide referral for neurocognitive assessment and 
rehabilitation as clinically indicated. 
 
Distress, Depression, and Anxiety 
Recommendation 4.5: It is recommended that primary care clinicians (a) Should assess 
patients for distress, depression, and/or anxiety (LOE=I); (b) Should conduct a more 
probing assessment for patients at a higher risk of depression (e.g., young patients, 
those with a history of prior psychiatric disease, and patients with low socioeconomic 
status) (LOE=III); (c) Should offer in-office counseling and/or pharmacotherapy and/or 
refer to appropriate psycho-oncology and mental health resources as clinically indicated 
if signs of distress, depression, or anxiety are present (LOE=I).   
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Clinical interpretation: Many cancer survivors report ongoing difficulties in recovery and 
returning to ‘normal’ following treatment1, 2, 17, 94. Some survivors of cancer experience fear of 
recurrence (FOR)95, contributing to significant mental health problems for which they may 
already have an increased risk, including distress, depression, and anxiety96, 97. Older age and 
African American breast cancer survivors have been found to have less FOR.  Shorter interval 
of time since diagnosis, having received chemotherapy, and having more symptoms, especially 
pain, were found to be related to higher levels of FOR98. Prevalence estimates for anxiety, 
depression, and distress in cancer survivors vary widely as a result of inconsistency in the use 
of measurement tools and differences in methodological approaches, such as the choice of 
comparators from the general population. The estimated prevalence of anxiety and depression 
is 17.9% and 11.6%, respectively, among the general cancer survivor population99. In a 
systematic review of observational studies, the prevalence of depression and anxiety among 
breast cancer survivors, specifically, was 22% (range=13-56%) using the Center for 
Epidemiological Studies for Depression (CES-D), 22% (range=17-48%) using the Beck 
Depression Inventory, and 10% (range=1-22%) using the Hospital Anxiety and Depression 
Scale100.  
In order to provide timely and appropriate support for their patients with a history of 
breast cancer, primary care clinicians should be familiar with the mental health concerns they 
may experience, the tools to screen for and assess these problems, and the resources to care 
for their patients. A tool for initial screening is the distress thermometer 
(http://www.nccn.org/patients/resources/life_with_cancer/pdf/nccn_distress_thermometer.pdf): 0 
(no distress) to 10 (extreme distress). A score of four or higher101 suggests a level of distress 
that has clinical significance. The PHQ-9102 and the GAD-7103 are validated methods for 
screening for depression and anxiety, respectively, and are available free online at 
http://www.phqscreeners.com/. For patients elevated on these screeners, further discussion and 
assessment of the issues is needed, as in the general population. For more information on 
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screening and assessing adults with cancer for psychosocial distress, see the depression and 
anxiety algorithms in the online Appendix which is reproduced from the ASCO guidelines15. 
The risk of having major depression after a diagnosis of breast cancer was higher 
among younger patients, patients with a history of prior psychiatric disease, patients with low 
socioeconomic status, and those who were unemployed104.  Among patients with breast cancer, 
decreased libido, poor self-image, and relationship issues were common among those who 
were depressed105-107.   
Treatment for depression and anxiety in cancer patients and survivors with medication 
and psychotherapy is comprehensively described in the recent ASCO anxiety and depression 
guideline adaptation (http://www.instituteforquality.org/screening-assessment-and-care-anxiety-
and-depressive-symptoms-adults-cancer-american-society) 15. In addition, or instead of 
pharmacotherapy, mindfulness-based approaches, expression of positive emotions, spiritual 
interventions, hope therapy, and meaning-making interventions have shown promise in 
addressing psychosocial needs of breast cancer survivors108. While the methodology studying 
the effectiveness of these interventions varied, survivors experienced positive changes, such as 
enhanced quality of life and well-being108. If a patient has a clinically significant score on any of 
the previously discussed instruments, it is recommended that primary care clinicians refer 
patients to the appropriate psychosocial oncology specialists, mental health professionals 
and/or resources in the community27. After referring to the appropriate resource(s), primary care 
clinicians should follow-up with patients to check their adherence to recommended therapies 
and/or assess the need for additional referrals. If a patient has difficulties with adherence to 
recommendations, primary care clinicians should identify the challenges with adherence and 
help the patient overcome these obstacles before discussing alternative interventions 15. The 
American Psychosocial Oncology Society website (http://www.apos-society.org/) can help 
primary care clinicians identify resources for their patients.  
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Where appropriate, these recommendations build upon the recently published ASCO 
screening, assessment and treatment of cancer-related fatigue guidelines among adult cancer 
survivors 25. 
Recommendation 4.6: It is recommended that primary care clinicians (a) Should assess 
for fatigue and treat any causative factors for fatigue, including anemia, thyroid 
dysfunction, and cardiac dysfunction (LOE= 0); (b) Should offer treatment or referral for 
factors that may impact fatigue (e.g. mood disorders, sleep disturbance, pain, etc.) for 
those who do not have an otherwise identifiable cause of fatigue (LOE= I); (c) Should 
counsel patients to engage in regular physical activity and refer for cognitive behavioral 
therapy as appropriate (LOE= I).  
Clinical interpretation: Cancer-related fatigue is very common among those treated for cancer, 
especially those who undergo treatment with radiation therapy and chemotherapy 13, 25, 109, with 
an estimated prevalence of 28% - 91% 110, 111. Recommendations for how to screen and assess 
for fatigue can be found in the online Appendix and come from ASCO’s guideline 25. For some, 
fatigue lasts long after treatment and can significantly interfere with QoL. Treatable causes of 
fatigue include anemia, thyroid dysfunction, and cardiac dysfunction 25. For those who do not 
have an identifiable physical cause of fatigue (i.e., anemia), contributing factors, such as mood 
disorders, sleep disturbance, and pain, should be addressed 25. Additional information related to 
distress/depression and pain can be found under Recommendation 4.5. 
A regular exercise regimen can reduce fatigue, help survivors feel better physically and 
emotionally and help them cope as has been demonstrated by several RCTs in breast cancer 
survivors 23, 25, 112 (see also Recommendation 5.3).  Cognitive behavioral therapy may also 
lessen fatigue113, 114. There are minimal data to support use of pharmacologic agents for 
management of fatigue in this population 25. Interventions should be tailored to the needs and 
abilities of the individual breast cancer survivor. ASCO has more detailed information on the 
Page 29 of 87 CA: A Cancer Journal for Clinicians

















Recommendation 4.7: It is recommended that primary care clinicians (a) Should refer 
post-menopausal breast cancer survivors for a baseline DEXA scan (LOE=0); (b) Should 
refer for repeat DEXA scans every 2 years for women taking an aromatase inhibitor, 
premenopausal women taking tamoxifen and/or a GnRH agonist, and women who have 
chemo-induced premature menopause (LOE=0).  
Clinical interpretation: The rate and magnitude of bone loss caused by cancer therapy is 
significantly higher than normal age-related bone loss115, 116. Up to 80% of breast cancer 
patients experience bone loss117, 118. Osteoporosis risk factors unique to patients following 
cancer therapy include chemotherapy-induced premature menopause, gonadotropin-releasing 
hormone (GnRH) suppression of gonadal function, antiestrogen therapies and 
glucocorticoids119. These risk factors are cumulative with other known risk factors, including age, 
prior fracture history and family history of fracture120, 121. Lifestyle-related factors, including 
smoking, excess alcohol, inadequate exercise, low calcium and vitamin D deficiency are 
common in this population and increase the risk of osteoporosis119. The primary care clinician 
should manage symptoms as he or she would in the general population.  
 Post-menopausal women treated with aromatase inhibitors are at increased risk of 
osteoporosis and should have initial and periodic (every 2 years) DEXA scan screening. If major 
risk factors change, a repeat DEXA scan at one year is reasonable to consider119. All post-
menopausal women or premenopausal women receiving ovarian suppression therapy with 
GnRH agonists are at risk for developing osteoporosis and should be screened according to the 
US Preventive Services Task Force31 and the American Association of Clinical Endocrinologists 
guide for postmenopausal osteoporosis diagnosis and treatment32.  
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            Initial strategies to reduce the morbidity associated with bone loss include education 
about risk factors and a healthy lifestyle. These should include physical activity and  regular 
weight-bearing exercise, avoiding tobacco use, limiting alcohol intake, and consider 
supplementation with calcium (to achieve a total intake of 1200mg/d) and Vitamin D3 (800-1000 
IU/day) for all adults > age 50 years119, 122-127. In addition to lifestyle and nutritional interventions, 
pharmacologic options should be considered in patients at high risk for bone loss and/or 
fracture119. Bisphosphonates or denosumab can prevent bone loss and/or treat established 
osteoporosis119, 128-130.  However, these drugs do have side effects and risks so that the risk vs. 
benefit of antiresorptive therapy must be carefully considered before starting therapy. Estrogen 
receptor modulators (raloxifene and tamoxifen) also have antiresorptive properties. However, in 
one large trial, combining a SERM and aromatase inhibitor blunted the reduction in breast 
cancer recurrence compared to AI alone. Therefore, SERM’s should not be used for the 
prevention of osteoporosis in women taking an aromatase inhibitor131. 
 
Musculoskeletal Health 
Recommendation 4.8: It is recommended that primary care clinicians (a) Should assess 
for musculoskeletal symptoms, including pain, by asking patients about their symptoms 
at each clinical encounter (LOE=0); (b) Should offer one or more of the following 
interventions based on clinical indication: acupuncture, physical activity, referral for 
physical therapy or rehabilitation (LOE=III).  
Clinical interpretation: Breast cancer survivors may report difficulties with the ipsilateral upper 
extremity following surgery, including decreased range of motion, rotator cuff injury, adhesive 
capsulitis (“frozen shoulder” with stiffness and pain in the shoulder joint), and axillary web 
syndrome (“cording” in the skin of the inner arm with sensations of pain and tightness that 
appear as a web or corded rope)132, 133. These abnormalities can lead to a decreased ability to 
perform activities of daily living and can impact employment. Systemic therapies for breast 
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cancer have also been associated with the development of musculoskeletal symptoms134. The 
prevalence of musculoskeletal symptoms among breast cancer patients varies greatly: shoulder 
range of motion (1.5-50%), musculoskeletal pain (12-51%), upper limb weakness (18-23%), and 
numbness (29-81%)132, 135-137. In particular, up to 50% of postmenopausal women receiving 
treatment with aromatase inhibitor medications report arthralgias (joint pain) and myalgias 
(muscle pain) which are severe enough in 20% of women to lead to treatment discontinuation138, 
139. These aromatase inhibitor associated musculoskeletal symptoms are often not responsive 
to nonsteroidal anti-inflammatory drugs and acetaminophen. Another option for treatment is to 
change from one anti-estrogen therapy to another. About 40% who discontinue the drug may 
tolerate a different AI or different formulation of the AI. The rest generally tolerate tamoxifen140. 
Poor compliance adherence to therapy has been shown to result in an increased risk of breast 
cancer recurrence, so helping patients manage their symptoms and encouraging drug 
compliance is important141. 
Physical therapy, including stretching and other exercises, has been shown to be 
effective for managing post-surgical musculoskeletal symptoms142, 143. Recent data from the 
Hormones and Physical Exercise trial, a prospective cohort study, demonstrated that 
participation in an intensive exercise regimen resulted in a 20% decrease in aromatase inhibitor-
associated pain144. To date, only acupuncture107 and exercise145 have been demonstrated to 
result in a statistically significant improvement in aromatase inhibitor-associated symptoms145, 
146.  
 
Pain and Neuropathy 
Recommendation 4.9: It is recommended that primary care clinicians (a) Should assess 
for pain and contributing factors for pain with the use of a simple pain scale and 
comprehensive history of the patient’s complaint (LOE=0). (b) Should offer interventions, 
such as acetaminophen, nonsteroidal anti-inflammatory drugs, physical activity and/or 
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acupuncture, for pain (LOE=I); (c) Should refer to an appropriate specialist depending on 
the etiology of the pain once the underlying etiology has been determined (e.g., 
lymphedema specialist, occupational therapist, etc.) (LOE=0); (d) Should assess for 
peripheral neuropathy and contributing factors for peripheral neuropathy by asking the 
patient about their symptoms, specifically numbness and tingling in their hands and/or 
feet, and the characteristics of that symptom (LOE=0); (e) Should offer physical activity 
for neuropathy (LOE=IA); (f) Should offer duloxetine for patients with neuropathic pain, 
numbness and tingling (LOE=IB).   
Clinical interpretation: A substantial percentage of breast cancer survivors experience long-term 
treatment-related chronic pain that can negatively impact QoL. Published reports demonstrate 
that 25-60% of breast cancer survivors experience chronic pain as a result of the treatments 
administered, including surgery, radiation therapy, chemotherapy, and endocrine therapy139, 147-
150.  
 Patients should also be evaluated for secondary causes of pain, such as lymphedema 
or tightness of the chest wall or axilla, and referred to lymphedema specialists or occupational 
therapists as indicated. Once the work-up and assessment are complete and underlying causes 
identified or ruled out, chronic pain following breast cancer surgery is typically treated with 
standard analgesics, including acetaminophen and nonsteroidal anti-inflammatory drugs.  
Acupuncture and physical activity have been shown in meta-analyses of RCTs to 
improve pain among breast cancer survivors and are typically used to complement traditional 
cancer care. Treatment-related joint pain among breast cancer survivors is quite commonly 
treated with acupuncture, with many trials and systematic reviews demonstrating its efficacy in 
decreasing pain intensity146, 151. However, evidence is lacking to show that acupuncture directly 
benefits breast cancer survivors who are experiencing cancer-induced peripheral neuropathy 
(CIPN). Physical activity has been shown in multiple RCTs to improve pain152 . 
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Neuropathy, including numbness, tingling, and burning pain, is also common following a 
diagnosis of breast cancer and subsequent treatment. It is particularly common following 
surgery and after treatment with taxane- or platinum-based chemotherapy regimens, reported in 
30-40% of patients149. ASCO recently published a Clinical Practice Guideline about the 
prevention and management of chemotherapy-induced peripheral neuropathy (CIPN; 
http://www.instituteforquality.org/prevention-and-management-chemotherapy-induced-
peripheral-neuropathy-survivors-adult-cancers)14 and we endorse this guideline.  
Prevention and treatment approaches for the management of CIPN in adult cancer 
survivors, reproduced from the ASCO guideline, are available in the online Appendix. In a few 
small RCTs with breast cancer survivors, physical activity has been shown to improve 
arthralgias, neuropathy, and neuropathy symptoms145, 153. A number of pharmaceutical agents 
have been tested for management of CIPN. The serotonin-norepinephrine reuptake inhibitor 
(SNRI), duloxetine, was shown in a randomized placebo-controlled trial to decrease neuropathic 
pain significantly more than placebo, and may also improve numbness and tingling. The trial 
used an initial dose of 30 mg daily for the first week to reduce the likelihood of nausea, which 
was then increased to 60 mg daily. Associated relative risk benefit was 30-50% in pain 
reduction154. Studies of tricyclic antidepressants and anticonvulsants have not demonstrated 
consistent significant improvements in symptoms. Additional recommendations for the 
prevention and management of chemotherapy-induced peripheral neuropathy can be found in 
the recently published ASCO guidelines14. 
 
Infertility 
Recommendation 4.10: It is recommended that primary care clinicians should refer 
survivors of childbearing age who experience infertility to a specialist in reproductive 
endocrinology and infertility as soon as possible (LOE=0). 
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Clinical interpretation: Infertility, as a result of cancer treatment, is a potential long-term side 
effect faced by younger breast cancer survivors (younger than age 45). When it occurs, it can 
have profound impact on a survivor’s physical, psychosocial, and QoL48.  Breast cancer cases 
among patients between the ages of 20 and 45 represent 10.9% of all new breast cancer cases 
in the United States2 making infertility an issue for many younger survivors155.  
Chemotherapy can be gonadotoxic leading to reduced fertility or early menopause 
secondary to premature ovarian failure77, 155. Many of the most frequently used chemotherapy 
agents in the treatment of breast cancer (e.g., alkylating agents, platinum agents, and taxanes) 
are also those that most often lead to premature ovarian failure156.  The incidence of 
chemotherapy-related amenorrhea increases with age, as the female ovarian reserve is 
nonrenewable and diminishes steadily with age. However, there is considerable variation in 
ovarian reserve in women of similar age157. There is limited literature related to the 
gonadotoxicity of biologics and targeted therapies and more studies are needed. Primary care 
clinicians should involve the treating medical oncologist in any potential discussion related to the 
optimal time for pregnancy after the completion of breast cancer treatment. Pre-menopausal 
women who desire pregnancy and are having difficulty conceiving for 6 months or more (or 
have had more than one miscarriage) should be referred to a fertility specialist. Timely referral is 
crucial due to the rapid loss of ovarian reserve in these women. 
 
Sexual Health 
Recommendation 4.11: It is recommended that primary care clinicians (a) Should assess 
for signs and symptoms of sexual dysfunction or problems with sexual intimacy 
(LOE=0); (b) Should assess for reversible contributing factors to sexual dysfunction and 
treat, when appropriate (LOE=0); (c) Should offer nonhormonal, water-based lubricants 
and moisturizers for vaginal dryness (LOE=IA); (d) Should refer for psychoeducational 
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support, group therapy, sexual counseling, marital counseling or intensive 
psychotherapy, when appropriate (LOE=IA). 
Clinical interpretation: Sexual complaints are a common problem among breast cancer survivors 
that should be assessed. They can include sexual desire disorder / decreased libido (23–64%), 
arousal or lubrication concerns (20-48%), orgasmic concerns (16-36%), and dyspareunia (35-
38%)77. Patients who were treated with chemotherapy tend to have more of these sexual 
concerns than those treated only with surgery and/or radiation50. Treatment with aromatase 
inhibitors may cause vaginal dryness, dyspareunia (which can be severe), menopausal 
symptoms, and loss of sexual desire158. Radiation therapy can often cause skin fibrosis, loss of 
sexual sensitivity of the skin, and uncommonly cardiac and respiratory damage, all of which 
negatively impact sexual desire and response159.    
It is important to counsel patients concerning possible sexual dysfunction remedies 
including treatments for vaginal dryness.  Nonhormonal, water-based lubricants and 
moisturizers remain the primary treatment160. Silicone-based products may last longer than 
water or glycerin-based products.  A combination of therapies may provide additional short-term 
comfort. Hormonal therapies, such as a low dose estrogen vaginal tablet or estradiol vaginal 
ring, may be recommended for vaginal dryness due to urogenital atrophy, although results 
commonly take approximately 6-12 weeks160, 161. The safety of these therapies in women with a 
history of breast cancer is not well established at this time. The level of estrogen absorption is 
variable, which raises concerns in patients with a history of breast cancer. Use of hormonal 
therapies for women on aromatase inhibitors is not recommended162. Treating dyspareunia 
secondary to vaginal atrophy and stenosis with vaginal dilators or pelvic floor relaxation 
techniques may be helpful77.   
Referral for interventions, such as brief psychoeducational support, group therapy, 
sexual counseling, marital counseling or intensive psychotherapy should be offered to all breast 
cancer survivors with sexual complaints specifically addressing possible anxiety, stress, 
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unpleasant symptoms including hot flashes, sexual comfort in lovemaking, and mood changes50, 
158, 163. Taken together, the trio of counseling, over-the-counter treatments, and pharmacologic 
treatments can do much to ameliorate the sexual issues caused by breast cancer and its 
management158.  See Recommendation 4.1 to address body image concerns.  
 
Premature Menopause/Hot Flashes 
Recommendation 4.12: It is recommended that primary care clinicians should offer 
selective serotonin-norepinephrine reuptake inhibitors (SNRIs), selective serotonin 
reuptake inhibitors (SSRIs), gabapentin, lifestyle modifications and/or environmental 
modifications to help mitigate vasomotor symptoms of premature menopausal 
symptoms (LOE=IA).  
Clinical interpretation: Women can experience menopausal symptoms if chemotherapy results 
in premature cessation of ovarian function or as a side effect of endocrine therapies. Vasomotor 
symptoms are typically more severe in younger survivors due to the abrupt change in 
hormones164 and when present, can have significant impact on QoL. For younger women on 
endocrine therapies, 50-70% will likely experience hot flashes while on tamoxifen77.   
Systemic hormone therapy is rarely, if ever, given to patients with breast cancer to 
control menopausal symptoms. Non-hormonal medications such as serotonin-norepinephrine 
reuptake inhibitors (SNRIs) and selective serotonin reuptake inhibitors (SSRIs) can decrease 
the intensity and severity of vasomotor symptoms, although are not FDA approved for this 
indication.  The SNRI, venlafaxine, has been found to be safe and effective at reducing hot 
flashes165.  There is concern that SSRIs that inhibit the CYP2D6 enzyme pathway, such as 
paroxetine, may reduce the conversion of tamoxifen to active metabolites, although a negative 
impact on breast cancer outcomes has not been conclusively demonstrated166. Consistent with 
recommendations by ASCO and NCCN, patients should not be screened for CYP2D6 9, 167. The 
anticonvulsant gabapentin has also been shown to be effective in reducing hot flashes168-170. 
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Similarly, the antihypertensive, clonidine, has been used in clinical practice171. Antihypertensive 
medications, lifestyle and environmental modifications may also help decrease the intensity and 
severity of menopausal symptoms. Acupuncture has been shown, in a meta-analysis of RCTs 
with breast cancer survivors, to reduce menopausal symptoms and hot flashes172. Lifestyle 
interventions, including rhythmic breathing, vitamins, exercise, and avoiding spicy foods 
caffeine, and alcohol, have had variable results. Environmental modifications such as cool 
rooms and dressing in layers can also be helpful. Complementary therapies have been studied 
and some have been found to be minimally effective 173. 
 
HEALTH PROMOTION 
Women with breast cancer are likely to have long-term survival1. Thus enhancing length 
and quality of life is an important goal in the care of patients with breast cancer and in creating a 
survivorship care plan (see Recommendations 5.1 and 6.1 for more information on Survivorship 
Care Plans). Healthy behaviors are paramount to reducing the risk of second cancers, 
comorbidities, obesity, and possibly recurrence; improving prognosis; ameliorating cancer-
related symptoms174-179; and decreasing risk of mortality176-186.  
Table 5 outlines this information, including physical activity, nutrition, and smoking 
cessation recommendations for breast cancer survivorship, incorporating existing ACS Nutrition 
and Physical Activity recommendations 23. 
(Table 5: Health Promotion Guidelines)   
 
Information 
Recommendation 5.1: It is recommended that primary care clinicians (a) Should assess 
the information needs of the patient related to breast cancer and its treatment, side 
effects, other health concerns, and available support services (LOE=0); (b) Should 
provide or refer survivors to appropriate resources to meet these needs (LOE=0). 
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Clinical interpretation: Breast cancer survivors often express unmet needs for information after 
treatment, including information on the effects of cancer treatment, emotional distress, and 
lifestyle changes187, 188. Younger breast cancer patients can be particularly vulnerable to the 
physical, emotional, and psychosocial late effects of treatment due to the aggressiveness of 
their disease, intensity of treatment plan48, 189, and based on younger age when a cancer 
diagnosis is not as common or expected 190, 191.  Treatment summaries and individualized 
survivorship care plans provide survivors with individualized information on their cancer care. 
However, to date, there exists inconsistency in their implementation, comprehensiveness, and 
perceived helpfulness for both patients and primary care clinicians63, 192-194. 
Results from randomized trials of survivorship care plans are mixed195-198 making the 
direct benefits of survivorship care plans less clear. However, failure of specialists to provide 
treatment summaries and survivorship care plans to primary care clinicians is an obstacle to 
primary care clinicians providing relevant information and care to their patients with a history of 
breast cancer. 
The informational needs of breast cancer survivors and caregivers should be routinely 
assessed and information about the long-term and late effects of breast cancer treatment, as 
well as information on risk reduction and health promotion, should be provided. Resources that 
may be beneficial to share with patients include the ACS Survivorship Center website 
(www.cancer.org/survivorshipcenter)62, the ACS website199, Journey Forward 
(www.journeyforward.org), the American Society of Clinical Oncology’s (ASCO) survivor and 
caregiver site (www.cancer.net), and the National Comprehensive Cancer Network (NCCN) 
patient and caregiver resources (http://www.nccn.org/patients/default.aspx). 
 
Obesity 
Recommendation 5.2: It is recommended that primary care clinicians (a) Should counsel 
survivors to achieve and maintain a healthy weight (LOE=III); (b) Should counsel 
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survivors if overweight or obese to limit consumption of high-calorie foods and 
beverages and increase physical activity to promote and maintain weight loss (LOE=IA, 
III).  
Clinical interpretation: Approximately 62% of breast cancer survivors are overweight/obese 
(have a BMI of least 25kg/m2), of which 30% are classified as obese (BMI 30kg/m2 or higher)200. 
Sufficient evidence documents obesity as a risk factor for post-operative complications, second 
cancers, risk of recurrence, development of diabetes, and other issues. Conversely, weight loss 
mitigates symptoms and improves quality of life 201. ASCO issued a position statement 
underscoring the need for oncology providers to counsel their patients about achieving a healthy 
weight 202.  Primary care clinicians should also counsel cancer survivors to achieve or maintain 
a healthy weight201 and refer to multi-component obesity treatment programs where appropriate 
203.   
 
Physical Activity 
Recommendation 5.3: It is recommended that primary care clinicians should counsel 
survivors to engage in regular physical activity consistent with the ACS guideline23 and 
specifically: (a) Should avoid inactivity and return to normal daily activities as soon as 
possible following diagnosis (LOE=III); (b) Should aim for at least 150 minutes of 
moderate or 75 minutes of vigorous aerobic exercise per week (LOE=I, IA); (c) Should 
include strength training exercises at least 2 days per week. Emphasize strength training 
for women treated with adjuvant chemotherapy or hormone therapy (LOE= IA).  
Clinical interpretation: Approximately 32% of cancer survivors meet the recommendations for 
physical activity204. Numerous systematic reviews and meta-analyses document the many 
health benefits from physical activity in breast cancer survivors, including mitigating treatment 
side-effects (i.e., fatigue) and improving quality of life and physical functioning. The data 
suggesting a potential survival benefit of physical activity come from observational data with the 
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most recent review of this literature citing 16 studies reporting an average relative risk of 0.72 
for breast cancer deaths in physically active breast cancer survivors (95% CI: .60-.85) and 0.52 
for all-cause mortality (95% CI: .42-.64) 205.  Breast cancer survivors should be advised to return 
to normal daily activities as soon as possible following diagnosis and continue to engage in 
regular physical activity.  Breast cancer survivors should strive to exercise at least 150 minutes 
moderately or 75 minutes vigorously per week and include strength training exercises at least 2 
days per week23. Additional details regarding the amount of time needed for each strength 
training session is less clear.  However, studies indicate that 37-53% of breast cancer survivors 
meet the aerobic guideline206, 207 and 23% meet the strength training guideline208. Observational 
evidence suggests greater amounts of activity may be needed although the evidence is 
insufficient to make this a recommendation at this time; aerobic exercise of 3 hours or more per 
week may be needed to improve breast cancer survival186, 209. 
 
Nutrition 
Recommendation 5.4: It is recommended that primary care clinicians should counsel 
survivors to achieve a dietary pattern that is high in vegetables, fruits, whole grains, and 
legumes, low in saturated fats (LOE= IA, III), and limited in alcohol consumption (LOE=0). 
Clinical interpretation: Only 18-34% of breast cancer survivors report eating 5 or more fruit and 
vegetables a day207. Eating a diet characterized by high amounts of vegetables, fruits, whole 
grains, and legumes (vs. a typical Western diet) has been associated with reduced risk (15-
43%) for all-cause mortality210-212.  Data from the two large RCTs of diet interventions in breast 
cancer survivors suggest that dietary change sufficient to result in weight loss may be needed to 
favorably impact breast cancer recurrence and prognosis 213, 214.  Per ACS Nutrition and 
Physical Activity Guidelines, alcohol consumption should be limited to no more than one drink 
per day for women, as in the general population215, 216. Data are inconsistent but suggest that 
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breast cancer survivors who consume more than 3 to 4 drinks per week are at increased risk for 
breast cancer recurrence217. 
Studies have shown that the carcinogenic ingredients of alcohol increase the risk of 
developing many types of cancers218-220 when alcohol, regardless of the type of  (i.e., wine, beer, 
etc), is consumed in excess of daily recommended limits221. Approximately 7% of breast cancer 
survivors report excessive drinking206. Based on these data, survivors should be counseled to: 
achieve a dietary pattern that is high in vegetables, fruits, whole grains, and legumes; limit 
alcohol intake to no more than one drink per day; and follow the ACS Guidelines on Nutrition 
and Physical Activity for Cancer Survivors 23 with a focus on successful weight management. 
 
Smoking Cessation 
Recommendation 5.5: It is recommended that primary care clinicians should counsel 
survivors to avoid smoking and refer survivors who smoke to cessation counseling and 
resources (LOE= I).  
Clinical interpretation: Approximately 10-12% of breast cancer survivors smoke206, 207. 
Numerous observational studies show that women who smoke at the time of diagnosis have 
substantially worse breast cancer-specific and overall survival than former and never 
smokers222.  A recent meta-analysis of this observational work documents a 33% increased risk 
of mortality from breast cancer in women who are smokers at diagnosis compared to former 
smokers 222. Survivors should discontinue smoking and avoid subsequent tobacco product use.  
Clinicians should identify smokers and motivate and encourage patients to quit through 
cessation programs, brochures and pamphlets, counseling, pharmacotherapy and regular 
follow-up223. These programs should be initiated at the time of initial diagnosis if possible.  
 
CARE COORDINATION / PRACTICE IMPLICATIONS 
(Table 6: Care Coordination Guideline) 
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There are no clear guidelines for the shared care and co-management of patients with 
breast cancer after the completion of active treatment. The time to transition is variable and 
dependent on medical, geographic, and resource restraints. Some patients return to their 
primary care clinician immediately after treatment is completed224-226. Others may choose to 
transition to their follow-up care only after they are considered at little or low risk for disease 
recurrence or late effects of cancer treatment227, 228. Several RCTs show that care led by 
primary care clinicians is as effective as hospital- or specialist-led care, including similar rates of 
recurrence-related serious clinical events, levels of health-related QoL229 , and patient 
satisfaction with care230 . 
Breast cancer survivors may continue to see their oncology team for follow-up disease 
surveillance; however, they should also be seen by their primary care clinician for health 
maintenance and management of co-morbidities that may or may not be related to their cancer 
diagnosis and treatment225, 231.  
 
Survivorship Care Plan 
Recommendation 6.1: It is recommended that primary care clinicians should consult with 
the cancer treatment team and obtain a treatment summary and Survivorship Care Plan 
(LOE=0, III).  
Clinical interpretation: Survivorship care plans are recommended as an important tool to 
facilitate communication and allocation of responsibility during the transition from active 
treatment to survivorship care 4, 232. A summary of a patient’s diagnosis and treatment received 
should be provided by the oncology care team when a patient with breast cancer transitions 
care to other providers; a treatment summary should describe the type and stage/side of the 
cancer, type of surgery, the name of the chemotherapy/hormones/biologics and cumulative 
doses of chemotherapy and the types and cumulative doses of radiation therapy, including the 
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fields and extent of the radiation 4, 192 .  Patients can initiate the building of a survivorship care 
plan process on ASCO’s website: http://www.cancer.net/survivorship/follow-care-after-cancer-
treatment/asco-cancer-treatment-and-survivorship-care-plans, at http://www.journeyforward.org/ 
or at http://www.livestrongcareplan.org/.  
Ideally, the oncology team should also work with the patient to develop an individualized 
cancer survivorship care plan for breast cancer survivors. This care plan guides 
recommendations for the type and timing of follow up imaging, laboratory tests, and office visits. 
The care plan should include information on the risk for late effects of treatment and what to 
watch for specifically based on the type of cancer and treatment received. Survivors should be 
assessed for the presence of these physical (e.g., cardiovascular issues, musculoskeletal 
issues), as well as psychosocial effects (e.g., cognitive dysfunction, depression, fear of 
recurrence, body image and sexual dysfunction) and be referred to the appropriate providers 
and services. 
The field of oncology is, however, broadly struggling with how to best meet this 
recommendation, and in identifying the specific benefits of such care plans.  Various tools and 
strategies to facilitate the creation and distribution of these care plans are being actively 
considered, for all tumor sites, including breast cancer.  Challenges in workflow and tools make 
this difficult currently but the field is working toward a sustainable solution.  
 
Communication with Oncology Team 
Recommendation 6.2: It is recommended that primary care clinicians should maintain 
communication with the oncology team throughout your patient’s diagnosis, treatment 
and post-treatment care to ensure care is evidence-based and well-coordinated (LOE=0). 
Clinical interpretation: Communication and cooperation among providers and survivors is 
critical, with the oncology team providing concrete recommendations for care when needed or 
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requested by other providers232. Clear communication regarding the respective roles of different 
members of the health-care team is critical to a successful transition to survivorship care.  
The primary care clinician should serve as a general medical care coordinator 
throughout the spectrum of breast cancer detection and aftercare, focusing on evidence-based 
preventive care and the management of preexisting comorbid conditions, regularly addressing 
the patient’s overall physical and psychosocial status, making appropriate referrals for 
psychosocial, rehabilitative, or other specialist care as needed, and coordinating those 
components of survivorship care that are agreed upon with the treating clinicians. Treatment of 
breast cancer is complex and rapidly changing; therefore, decisions about and coordination of 
cancer treatment should be left to the oncology team. 
 
Inclusion of Family 
Recommen ation 6.3: It is recommended that primary care clinicians should encourage 
the inclusion of caregivers, spouses, or partners in usual breast cancer survivorship 
care and support (LOE=0).   
Clinical interpretation: Caregivers have to cope with the physical aftermath of the survivors’ 
treatment and manage their long-term and late effects, in addition to their own psychosocial and 
physical unmet needs233. Research has shown that for 14-24 months after a survivor’s cancer 
diagnosis, caregivers provide consistent, continuing care involvement234 for patients following 
breast cancer treatment. Successful coordination of care involves not only a comprehensive 
care team, including primary care clinicians, but also the informal caregivers (usually the 
spouse/partner/family member) who provide ongoing care to cancer survivors in the home235. 
Furthermore most caregivers are older adults who are also managing their own health 
problems. When possible, primary care clinicians should include caregivers of breast cancer 
survivors in all follow-up care appointments to optimize survivor wellness.  
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A significant limitation of this guideline is the limited evidence-base to provide clear and 
specific recommendations for the prevention and management of long-term and late effects of 
cancer survivors. There are few prospective, randomized controlled trials testing interventions 
among breast cancer survivors even though studies in breast cancer survivors dominate the 
survivorship literature. The majority of the citations characterizing the risk and magnitude of risk 
of late effects and management recommendations rely predominantly on case-control studies 
with fewer than 500 participants and reviews that combine studies with varying outcome 
measures. There were several cohort studies that used population-based data to estimate the 
risk of late effects.    
Another limitation is the reliance on previous guidelines for surveillance and symptom 
management. Additionally, the literature review was not managed by a clinical epidemiologist 
due to limite  resources; and instead was conducted by project staff and an ACS librarian. 
Furthermore, the guidelines did not result directly from the development of specific clinical 
questions asked prior to the literature review; and guidelines included in the literature review 
were not evaluated through an instrument such as the Rigor of Development subscale of the 
Appraisal for Guidelines for Research and Evaluation (AGREE II). Recommendations are based 
on current evidence in the literature, but most evidence is not sufficient to warrant a strong 
recommendation. Rather, recommendations should be largely seen as possible management 
strategies given the current limited evidence base. 
HEALTH DISPARITIES 
 
Although the ACS/ASCO clinical practice guidelines represent expert recommendations 
on the best practices in disease management to provide the highest level of cancer care, it is 
important to note that many patients have limited access to medical care. Racial and ethnic 
disparities in health care contribute significantly to this problem in the United States. Patients 
with cancer who are members of racial/ethnic minorities suffer disproportionately from 
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comorbidities, experience more substantial obstacles to receiving care, are more likely to be 
uninsured, and are at greater risk of receiving care of poor quality than other Americans 236-239.  
Many other patients lack access to care because of their geographic location and distance from 
appropriate treatment facilities. Awareness of these disparities in access to care should be 
considered in the context of this clinical practice guideline, and health care providers should 
strive to deliver the highest level of cancer care to these vulnerable populations. 
 
ACS and ASCO believe that cancer clinical trials are vital to inform medical decisions 
and improve cancer care, and that all patients should have the opportunity to participate.    
 
 
MULTIPLE CHRONIC CONDITIONS 
 
Creating evidence-based recommendations to inform treatment of patients with 
additional chronic conditions, a situation in which the patient may have two or more such 
conditions—referred to as multiple chronic conditions (MCC)—is challenging 240. Patients with 
MCC are a complex and heterogeneous population, making it difficult to account for all of the 
possible permutations to develop specific recommendations for care. In addition, the best 
available evidence for treating index conditions, such as cancer, is often from clinical trials 
whose study selection criteria may exclude these patients in order to avoid potential interaction 
effects or confounding of results associated with MCC. As a result, the reliability of outcome 
data from these studies may be limited, thereby creating constraints for expert groups to make 
recommendations for care in this heterogeneous patient population.  
As many patients for whom guideline recommendations apply present with MCC, any 
treatment plan needs to take into account the complexity and uncertainty created by the 
presence of MCC and highlights the importance of shared decision making regarding guideline 
use and implementation. Therefore, in consideration of recommended care for the target index 
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condition, clinicians should review all other chronic conditions present in the patient and take 
those conditions into account when formulating the treatment and follow-up plan. 
In light of the above considerations, practice guidelines should provide information on how to 
apply the recommendations for patients with MCC, perhaps as a qualifying statement for 
recommended care. This may mean that some or all of the recommended care options are 




After finalization by the workgroup, the guideline manuscript was sent to additional internal 
(ACS and ASCO) and external experts for review and comment prior to submission for 
publication. Review comments were reviewed by the Expert Panel and integrated into the final 





ACS/ASCO guidelines are developed for implementation across health settings. Barriers to 
implementation include the need to increase awareness of the guideline recommendations 
among front-line practitioners and survivors of cancer and caregivers, and also to provide 
adequate services in the face of limited resources. The guideline Bottom Line Box was designed 
to facilitate implementation of recommendations. This guideline will be distributed widely 
through the ASCO Practice Guideline Implementation Network.  ACS/ASCO guidelines are 
posted on the ACS Website and ASCO Website.  This joint ACS-ASCO guideline is also 
published in the Journal of Clinical Oncology.  
 
SUMMARY 
Breast cancer survivors face potentially significant impacts of cancer and its treatment 
and deserve high-quality, comprehensive, coordinated clinical follow-up care. Primary care 
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clinicians must consider each patient’s individual risk profile and preferences of care to address 
physical and psychosocial impacts. Survivors should be provided support to address fear of 
recurrence, depression, anxiety, cognitive impairment, body image issues, sexual concerns, 
functional changes and physical impairments, relationship changes, other social role difficulties, 
employment concerns, and financial challenges, among others. Breast cancer survivors also 
need to be counseled on health promotion strategies to minimize and mitigate long-term and 
late effects, ameliorate comorbid health conditions and to potentially increase survival.  
To clarify the roles of all clinicians working with cancer survivors, we concur with the IOM 
that survivors and primary care clinicians receive a survivorship care plan, which includes a 
concise summary of treatment as well as a clinical follow-up care plan. Ideally, this plan would 
be constructed in partnership with the survivor to identify and prioritize goals for survivorship 
care and would be communicated to the patient to ensure understanding of individual risks; 
recommended tests, procedures and supportive care strategies; and how to optimize wellness. 
Survivorship care should be coordinated with treating cancer specialists. 
 
ADDITIONAL RESOURCES 
In addition to this guideline, tools and resources are available to assist primary care 
clinicians in implementing these recommendations. The CA Journal offers the CA Patient Page 
(publisher insert URL) to help patients understand how to use this guideline to talk to their 
doctor about surveillance and screening, symptom management, healthy behaviors and care 
coordination. The Survivorship Center also offers The GW Cancer Institute’s Cancer 
Survivorship E-Learning Series for Primary Care Providers (The E-Learning Series), a free, 
innovative online continuing education program to educate primary care clinicians about how to 
better understand and care for survivors in the primary care setting. Continuing education 
credits are available at no cost to physicians, nurse practitioners, nurses and physician 
assistants for each 1-hour module. Learn more about The E-learning Series at 
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www.cancersurvivorshipcentereducation.org. Visit www.asco.org/guidelineswiki to provide 
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Table 1: Guideline for Surveillance for Breast Cancer Recurrence and Genetic Counseling 
It is recommended that primary care clinicians: Level of Evidence
a
 
1.1 History and Physical 
(a) Should individualize clinical follow-up care provided to breast 
cancer survivors based on age, specific diagnosis and treatment 
protocol as recommended by the treating oncology team.  
(b) Should make sure the patient receives a detailed cancer-related 
history and physical examination every 3 to 6 months for the first 3 
years after primary therapy, every 6 to 12 months for the next 2 years, 






1.2 Screening the Breast for Local Recurrence or a New Primary Breast 
Cancer 
(a) Should refer women who have received a unilateral mastectomy 
for annual mammography on the intact breast and for those with 
lumpectomies an annual mammography of both breasts. 
(b) Should not refer for routine screening with MRI of the breast 
unless the patient meets high risk criteria for increased breast cancer 






1.3 Laboratory Tests and Imaging 
Should not offer routine laboratory tests or imaging, except 
mammography if indicated, for the detection of disease recurrence in the 






1.4 Signs of Recurrence 
Should educate and counsel all women about the signs and symptoms of 






1.5 Risk Evaluation and Genetic Counseling 
(a) Should assess your patient’s cancer family history.  
(b) Should offer genetic counseling if potential hereditary risk factors 
are suspected (e.g., women with a strong family history of cancer 







1.6 Endocrine Treatment Impacts, Symptom Management 









Level of evidence: I, meta-analyses of randomized controlled trials (RCTs); IA, RCT of breast 
cancer survivors; IB, RCT based on cancer survivors across multiple sites; IC, RCT not based on 
cancer survivors but on general population experiencing a specific long-term or late effect (eg, 
managing fatigue, lymphedema, etc); IIA, non-RCT based on breast cancer survivors; IIB, non-
RCT based on cancer survivors across multiple sites; IIC, non-RCT not based on cancer 
survivors but on general population experiencing a specific long-term or late effect (eg, 
managing urinary incontinence, erectile dysfunction, etc); III, case-control or prospective cohort 
study; 0, expert opinion, observation, clinical practice, literature review, or pilot study.; 
b
National Comprehensive Cancer Network rating 2A indicates that “based upon lower-level 
evidence, there is uniform consensus that the intervention is appropriate”;
 c
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Table 2: ACS Guidelines for the Early Detection of Cancer in Average Risk, Asymptomatic 
Individuals 
 
Recommendation 2.1: Among average risk patients, it is recommended that primary care 
clinicians: 
(a) Should screen for other cancers as they would for patients in the general population. 
(b) Should provide an annual gynecological assessment for post-menopausal women on selective 




POPULATION TEST OR 
PROCEDURE 
FREQUENCY 
Cervix Women, aged 
21-65 y 
Pap test and 
HPV DNA test 
Cervical cancer screening should begin at 
age 21 y. For women aged 21-29 y, 
screening should be done every 3 y with 
conventional or liquid-based Pap tests. 
For women aged 30-65 y, screening 
should be done every 5 y with both the 
HPV test and the Pap test (preferred), or 
every 3 y with the Pap test alone 
(acceptable). Women aged >65 y who 
have had ≥3 consecutive negative Pap 
tests or ≥2 consecutive negative HPV and 
Pap tests within the last 10 y, with the 
most recent test occurring within the last 5 
y, and women who have had a total 
hysterectomy should stop cervical cancer 
screening if they no longer have a cervix 
and are without a history of CIN2 or a 
more severe diagnosis in the past 20 y or 
cervical cancer ever. Women at any age 






FOBT with at 
least 50% test 
sensitivity for 
cancer, or FIT 
with at least 
50% test 
sensitivity for 





Annual, starting at age 50 y. Testing at 
home with adherence to manufacturer's 
recommendation for collection techniques 
and number of samples is recommended. 
FOBT with the single stool sample 
collected on the clinician's fingertip 
during a DRE in the health care setting is 
not recommended. Guaiac-based toilet 
bowl FOBT tests also are not 
recommended. In comparison with 
guaiac-based tests for the detection of 
occult blood, immunochemical tests are 
more patient-friendly, and are likely to be 
equal or better in sensitivity and 











































































specificity. There is no justification for 
repeating FOBT in response to an initial 
positive finding. 
  Stool DNA 
test,
b
 or  
Interval uncertain, starting at age 50 y. 
 
  FSIG, or Every 5 y, starting at age 50 y. FSIG can 
be performed alone, or consideration can 
be given to combining FSIG performed 
every 5 y with a highly sensitive guaiac-
based FOBT or FIT performed annually. 
  DCBE or  Every 5 y, starting at age 50 y. 
  Colonoscopy  Every 10 y, starting at age 50 y. 
  CT 
colonography 





 At the time of menopause, women at 
average risk should be informed about the 
risks and symptoms of endometrial cancer 
and strongly encouraged to report any 
unexpected bleeding or spotting to their 
physicians. 
Lung Current or 
former smokers 
aged 55-74 y in 
good health with 
at least a 30 
pack-y history 
LDCT Clinicians with access to high-volume, 
high-quality lung cancer screening and 
treatment centers should initiate a 
discussion about lung cancer screening 
with apparently healthy patients aged 55-
74 y who have at least a 30 pack-y 
smoking history, and who currently 
smoke or have quit within the past 15 y. A 
process of informed and shared decision-
making with a clinician related to the 
potential benefits, limitations, and harms 
associated with screening for lung cancer 
with LDCT should occur before any 
decision is made to initiate lung cancer 
screening. Smoking cessation counseling 
remains a high priority for clinical 
attention in discussions with current 
smokers, who should be informed of their 
continuing risk of lung cancer. Screening 







 On the occasion of a periodic health 
examination, the cancer-related checkup 
should include examination for cancers of 
the thyroid, ovaries, lymph nodes, oral 
cavity, and skin, as well as health 











































































counseling about tobacco, sun exposure, 
diet and nutrition, risk factors, sexual 
practices, and environmental and 
occupational exposures. 
ACS indicates American Cancer Society; BSE, breast self-examination; CBE, clinical breast 
examination; Pap, Papanicolaou; HPV, human papillomavirus; FOBT, fecal occult blood test; 
FIT, fecal immunochemical test; FSIG, flexible sigmoidoscopy; DCBE, double-contrast 
barium enema; CT, computed tomography; LDCT, low-dose helical CT. 
a
 Beginning at age 40 y, annual CBE should ideally be performed prior to mammography. 
b
 The stool DNA test approved for colorectal cancer screening in 2008 is no longer 
commercially available. New stool DNA tests are presently undergoing evaluation and may 














































































































Table 3: Summary of Long-term and Late Effects by Treatment Type 
Treatment Type Long-Term Effects Late Effects 
Surgery • Lack of skin sensitivity 
• Body image issues  
• Sexual dysfunction 
• Numbness 
• Pain 
• Limited range of motion 
• Weakness  
• Poor cosmetic outcome 
• Lymphedema 
• Neuropathy 




• Fatigue *^ 
• Skin sensitivity/pain 
• Sexual dysfunction 
• Pain 
• Pneumonitis*^ 
• Poor cosmetic outcome 




• Numbness or weakness of 
the upper extremity* 
 
* Risks are increased in 
patients who had RT also to 
the supraclavicular nodes 
  
^ Risks are increased in 
patients who had RT also to 
the internal mammary nodes 
 
 
• Skin discoloration 
• Breast may be slightly 
smaller and firmer than 
the non-irradiated side 
(breast asymmetry). 
• Skin sensitivity/pain 
• Telangiectasia 
• Sexual dysfunction 
• Lymphedema* 
• Shortness of breath (lung 
pneumonitis or fibrosis)* 
^ 
• Cardiovascular disease 
(e.g. pericardial effusion, 
pericarditis)^ 
• Numbness or weakness of 
the upper extremity*# 
• Second primary cancers 
(e.g., soft-tissue sarcomas 
of thorax, shoulder and 
pelvis; lung cancer)*^ 
 
* Risks are increased in 
patients who had RT also to 
the supraclavicular nodes 
 
^ Risks are increased in 
patients who had RT also to 
the internal mammary nodes 
 
# Need to be careful as these 
can also be signs of recurrent 
cancer, typically with pain. 
Appropriate consultation with 











































































the radiation oncologist may 
be warranted.  
Chemotherapy 
 
• Cognitive impairment 
• Fatigue  
• Ovarian failure with or 
without menopausal 
symptoms  
• Sexual dysfunction 
• Change in libido 
• Infertility 
• Weight gain 
• Obesity 
• Neuropathy, especially 
after taxanes 
• Oral health issues  
• Hair loss 
• Osteoporosis/osteopenia 
• Increased risk of 
cardiovascular disease 
(cardiomyopathy, 
congestive heart failure) 
with anthracycline-based 
chemotherapy 
• Increased risk of leukemia 
and myelodysplastic 
syndrome with alkylating 
agents, anthracyclines, 
other topoisomerase II 
inhibitors, and other 
agents with 
immunosuppressive 
potential   
Hormonal Therapy   
• Tamoxifen 
 
• Hot flashes 
• Changes in menstruation 
• Mood changes 
• Increased triglycerides 
 
 
• Increased risk of stroke 
• Increased risk of 
endometrial cancer 
• Increased risk of blood 
clots 
• Osteopenia in pre-
menopausal women 
• Aromatase inhibitors 
 
• Vaginal dryness 
• Decreased libido 
• Musculoskeletal 
symptoms/pain 
• Cholesterol elevation 
• Increased risk of 
osteoporosis 









General Psychosocial Long-term and Late Effects 
• Depression 
• Distress – multi-factorial unpleasant experience of psychological, social, and/or spiritual 
nature 
• Worry, anxiety 
• Fear of recurrence  
• Fear of pain 
• End of life concerns: death and dying 
• Loss of sexual function and/or desire 
• Challenges with body image  











































































• Challenges with self-image 
• Relationship and other social role difficulties 
• Return to work concerns and financial challenges 
Note:  
Long term effect is something that starts during treatment and does not subside, such as pain, 
fatigue, cognitive changes.   
In contrast, a late effect is something that develops much later, such as a second malignancy, 
heart failure, lymphedema.  Some long term effects are the same or overlap with late effects, for 































































































Table 4: Guideline for Assessment and Management of Physical and Psychosocial Long-term / 
Late Effects  
It is recommended that primary care clinicians: Level of Evidence
a
 
4.1 Body Image Concerns 
(a) Should assess for patient body image/appearance concerns.  
(b) Should offer the option of adaptive devices (e.g., breast prostheses, 
wigs) and/or surgery when appropriate.  
(c) Should refer for psychosocial care as indicated. 
 
0 (assessment) 





(a) Should counsel survivors on how to prevent / reduce risk of 
lymphedema, including weight loss for those who are overweight or 
obese. 
(b) Should refer patients with clinical symptoms or swelling 
suggestive of lymphedema to a therapist knowledgeable about the 
diagnosis and treatment of lymphedema, such as a physical therapist, 










(a): Should monitor lipid levels and provide cardiovascular 
monitoring, as indicated. 
(b) Should educate breast cancer survivors on healthy lifestyle 
modifications, potential cardiac risk factors, and when to report 







4.4 Cognitive Impairment 
(a) Should ask patients if they are experiencing cognitive difficulties.  
(b) Should assess for reversible contributing factors of cognitive 
impairment and optimally treat when possible.  
(c) Should refer patient with signs of cognitive impairment for 
neurocognitive assessment and rehabilitation, including group 
cognitive training if available. 




IA (group cognitive 
rehabilitation) 
4.5 Distress, Depression, and Anxiety 
(a) Should assess patients for distress, depression, and/or anxiety.  
(b) Should conduct a more probing assessment for patients at a higher 
risk of depression (e.g., young patients, those with a history of prior 
psychiatric disease, and patients with low socioeconomic status).  
(c) Should offer in-office counseling and/or pharmacotherapy and/or 
refer to appropriate psycho-oncology and mental health resources as 









(a) Should assess for fatigue and treat any causative factors for fatigue, 
including anemia, thyroid dysfunction, and cardiac dysfunction.  
(b) Should offer treatment or referral for factors that may impact 
fatigue (e.g., mood disorders, sleep disturbance, pain, etc.) for those 




I (causative factors) 
 
 











































































(c) Should counsel patients to engage in regular physical activity and 
refer for cognitive behavioral therapy (CBT) as appropriate. 
I (physical activity; 
CBT) 
4.7 Bone Health 
(a) Should refer post-menopausal breast cancer survivors for a 
baseline DEXA scan.  
(b) Should refer for repeat DEXA scans every 2 years for women 
taking an aromatase inhibitor, premenopausal women taking 
tamoxifen and/or a GnRH agonist, and women who have chemo-




0 (high risk) 
4.8 Musculoskeletal Health 
(a) Should assess for musculoskeletal symptoms, including pain, by 
asking patients about their symptoms at each clinical encounter.  
(b) Should offer one or more of the following interventions based on 
clinical indication: acupuncture, physical activity, referral for physical 





4.9 Pain and Neuropathy 
(a) Should assess for pain and contributing factors for pain with the 
use of a simple pain scale and comprehensive history of the patient’s 
complaint  
(b) Should offer interventions, such as acetaminophen, nonsteroidal 
anti-inflammatory drugs, physical activity and/or acupuncture, for 
pain.  
(c) Should refer to an appropriate specialist depending on the etiology 
of the pain once the underlying etiology has been determined (e.g., 
lymphedema specialist, occupational therapist, etc.).   
(d) Should assess for peripheral neuropathy and contributing factors 
for peripheral neuropathy by asking the patient about their symptoms, 
specifically numbness and tingling in their hands and/or feet, and the 
characteristics of that symptom.  
(e) Should offer physical activity for neuropathy. 
(f) Should offer duloxetine for patients with neuropathic pain, 

















4.10 Infertility  
Should refer survivors of childbearing age who experience infertility to a 




4.11 Sexual Health 
(a) Should assess for signs and symptoms of sexual dysfunction or 
problems with sexual intimacy.  
(b) Should assess for reversible contributing factors to sexual 
dysfunction and treat, when appropriate.  
(c) Should offer nonhormonal, water-based lubricants and moisturizers 
for vaginal dryness.  
(d) Should refer for psychoeducational support, group therapy, sexual 












4.12 Premature Menopause/Hot Flashes IA (SNRI and SSRI 











































































Should offer selective serotonin-norepinephrine reuptake inhibitors 
(SNRIs), selective serotonin reuptake inhibitors (SSRIs), gabapentin, 
lifestyle modifications and/or environmental modifications to help 
mitigate vasomotor symptoms of premature menopausal symptoms. 
use) 
a 
Level of evidence: I, meta-analyses of randomized controlled trials (RCTs); IA, RCT of breast 
cancer survivors; IB, RCT based on cancer survivors across multiple sites; IC, RCT not based on 
cancer survivors but on general population experiencing a specific long-term or late effect (eg, 
managing fatigue, lymphedema, etc); IIA, non-RCT based on breast cancer survivors; IIB, non-
RCT based on cancer survivors across multiple sites; IIC, non-RCT not based on cancer 
survivors but on general population experiencing a specific long-term or late effect (eg, 
managing urinary incontinence, erectile dysfunction, etc); III, case-control or prospective cohort 
study; 0, expert opinion, observation, clinical practice, literature review, or pilot study. 
 
 











































































Table 5: Health Promotion Guideline 




(a) Should assess the information needs of the patient related to breast 
cancer and its treatment, side effects, other health concerns, and 
available support services.  






(a) Should counsel survivors to achieve and maintain a healthy weight. 
(b) Should counsel survivors if overweight or obese to limit 
consumption of high-calorie foods and beverages and increase 
physical activity to promote and maintain weight loss. 
0 (maintenance) 
 
IA, III (weight loss) 
5.3 Physical Activity 
Should counsel survivors to engage in regular physical activity consistent 
with the ACS guideline and specifically: 
(a) Should avoid inactivity and return to normal daily activities as 
soon as possible following diagnosis.  
(b) Should aim for at least 150 minutes of moderate or 75 minutes of 
vigorous aerobic exercise per week.  
(c) Should include strength training exercises at least 2 days per week. 
Emphasize strength training for women treated with adjuvant 
chemotherapy or hormone therapy. 
 
 
III (avoid inactivity) 
 






Should counsel survivors to achieve a dietary pattern that is high in 
vegetables, fruits, whole grains, and legumes, low in saturated fats, and 
limited in alcohol consumption. 
 
IA, III (nutrition) 
 
0 (alcohol) 
5.5 Smoking Cessation 
Should counsel survivors to avoid smoking and refer survivors who 
smoke to cessation counseling and resources. 
I 
a 
Level of evidence: I, meta-analyses of randomized controlled trials (RCTs); IA, RCT of breast 
cancer survivors; IB, RCT based on cancer survivors across multiple sites; IC, RCT not based on 
cancer survivors but on general population experiencing a specific long-term or late effect (eg, 
managing fatigue, lymphedema, etc); IIA, non-RCT based on breast cancer survivors; IIB, non-
RCT based on cancer survivors across multiple sites; IIC, non-RCT not based on cancer 
survivors but on general population experiencing a specific long-term or late effect (eg, 
managing urinary incontinence, erectile dysfunction, etc); III, case-control or prospective cohort 
study; 0, expert opinion, observation, clinical practice, literature review, or pilot study











































































Table 6: Care Coordination Guideline 
It is recommended that primary care clinicians: Level of Evidence
a
 
6.1 Survivorship Care Plan 
Should consult with the cancer treatment team and obtain a treatment 
summary and Survivorship Care Plan. 
0, III 
6.2 Communication with Oncology Team 
Should maintain communication with the oncology team throughout your 
patient’s diagnosis, treatment and post-treatment care to ensure care is 
evidence-based and well-coordinated. 
0 
6.3 Inclusion of Family 
Should encourage the inclusion of caregivers, spouses, or partners in usual 
breast cancer survivorship care and support. 
0 
a 
Level of evidence: I, meta-analyses of randomized controlled trials (RCTs); IA, RCT of breast 
cancer survivors; IB, RCT based on cancer survivors across multiple sites; IC, RCT not based on 
cancer survivors but on general population experiencing a specific long-term or late effect (eg, 
managing fatigue, lymphedema, etc); IIA, non-RCT based on breast cancer survivors; IIB, non-
RCT based on cancer survivors across multiple sites; IIC, non-RCT not based on cancer 
survivors but on general population experiencing a specific long-term or late effect (eg, 
managing urinary incontinence, erectile dysfunction, etc); III, case-control or prospective cohort 
study; 0, expert opinion, observation, clinical practice, literature review, or pilot study. 
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*In this algorithm the use of the word depression refers to the PHQ-9screening scale and not to a clinical diagnosis  
1. Initial diagnosis/start of treatment, regular intervals during treatment, 3, 6, and 12 months post treatment, diagnosis of at recurrence or progression, when approaching 
death and during times of personal transition or re-appraisal such as family crisis (CAPO guideline: “Assessment of Psychosocial Health Care Needs of the Adult Cancer 
Patient” by Howell et al, 2009; Cancer Care Nova Scotia Distress Management Pathways, draft 2010). 
2. Presence of symptom in the last two weeks, rated as follows: 0 = not at all, 1 = several days, 2 = more than half the days, and 3 = nearly every day. 
3. Content of remaining 7 Items:  sleep problems, low energy, appetite, low self view, concentration difficulties, motor retardation or agitation, and thoughts of self harm. 
  
Note:  Reference for PHQ-9 cutoff >8 is Thekkkumpurath et al., (2011).  Screening for MDD in CA outpatients.  Cancer.  
If patient reports a 
score of 0 or 1 
If patient reports a score 
of 2 or 3 




Identify pertinent history / specific risk factors for depression  
 History:  Prior depressive disorder, with/without prior treatment 
 History:  Familial history of depression, with/without prior treatment 
 History:  Persons with other psychiatric disorders (e.g., GAD), including substance abuse 
 Recurrent, advanced, or progressive disease  
 Presence of chronic illness(es) in addition to cancer 
 Singleton (single not married, widowed, divorced) vs. partnered 
 Unemployed or lower socioeconomic status  





If at any time there is risk of harm to self and/or to others: 
If YES > Referral for emergency evaluation; Facilitate safe environment; One-to-one observation; Initiate interventions to reduce risk of harm to self and/or 
others. (The presence of other symptoms, e.g., psychosis, severe agitation and confusion (delirium), may also warrant emergency evaluation).    




: 1) Little interest or pleasure in doing things (anhedonia)  
                                                        2) Feeling down, depressed or helpless (depressed mood) 
 
 
 Has most depressive symptoms 
 Symptoms interfere moderately to 
markedly with functioning  
 Referral to psychology and/or psychiatry 
for diagnosis and treatment 
None/Mild Symptomatology 
(Score 1-7) 
Moderate Severe Symotomatology 
(Score 15-19)  
Severe Symptomatology 
 (Score 20-27) 
No Further Screening 
Moderate Severe Symotomatology  
Severe Symptomatology 
 No or minimal symptoms of 
depression  
 Effective coping skills and 
access to social support 
 Written materials as appropriate 
 Subthreshold depressive symptoms 
 Functional impairment from ‘mild’ 
to ‘moderate’  
 Seek consultation (psychology or 
psychiatry) for determination of 
diagnosis   
Screening and Assessment  – Depression in Adults with Cancer 
Screen at pre diagnosis, other times, and as is relevant1 








































































Care Map – Depression in Adults with Cancer 
 Offer referral to supportive care 
services  
 
Intervention Options (low intensity) 
 Individual guided self-help (or computerized) based 
on cognitive behavior therapy (CBT); including 
behavioral activation and problem solving)  
 Group based CBT for depression 
 Psychosocial interventions (group) 
 Structured physical activity program 
 Pharmacologic, as appropriate 
 
Intervention Options (high intensity) 
 Psychological (individual: CBT, 
Interpersonal Therapy) 
 Pharmacologic 
 Combined  
 
Psychological (individual) 
 Delivered by licensed mental health professionals using relevant treatment manuals which may include some or all 
of the following content:  cognitive change, behavioral activation, biobehavioral strategies, education, and/or 
relaxation strategies.   
 Relapse prevention additions are also important.   
 Monitor for efficacy.   
 Behavioral couples’ therapy can be considered for people with a regular partner and where the relationship may 
contribute to the development or maintenance of depression.  
Supportive Care Services for All Patients, As Available and Appropriate 
Provide education and information (verbal plus any relevant materials) for the patient and family about: 
 Normalcy of stress in the context of cancer  
 Specific stress reduction strategies (e.g., progressive muscle relaxation) 
 Sources of informational support/resources (patient library, reliable internet sites)  
 Availability of supportive care services (e.g., professionally led groups, informational lectures, volunteer organizations) for the 
patient and family at the institution or in the community  
 Availability of financial support (e.g., accommodations, transportation, health/drug benefits) 
 Information about signs and symptoms of depression if stress or distress worsen and avenues for care 
 Information on sleep hygiene and self-management of fatigue  
 Information on other non-pharmacological interventions (physical activity, nutrition)  
Pharmacological 
 Anti-depressants, with choice informed by side effect profiles, interactions, response, patient age and preference.  
 Consider interventions with short term duration.   
 Monitor regularly for adherence, side effects, and adverse events. 
Psychosocial (group) 
 Structured, professionally led, with topics such as: stress reduction, positive coping (seeking information, problem 
solving, assertive communication), enhancing social support from friends/family, coping with physical symptoms 
(e.g., fatigue, sexual dysfunction) and bodily changes, and health behavior change (diet, activity level, tobacco 
use).   
 Consider for individual treatment should depressive symptoms not remit or worsen. 
None/Mild Symptoms 
 
Care Pathway 1 
Supportive Care and Prevention 
 
Moderate Symptoms  
 
Care Pathway 2 
Psychological (group) or Psychosocial 
 
Moderate Severe to Severe 
Symptoms 
 
Care Pathway 3 
Psychological (individual) and/or Psychiatric 
 
Follow-up and ongoing re-assessment  
It is common for persons with depressive symptoms to lack the motivation necessary to follow through on referrals and/or to comply with treatment 
recommendations. With this in mind, on a bi-weekly or monthly basis, until symptoms have remitted: 
 Assess follow-through and compliance with individual or group psychological/psychosocial referrals, as well as satisfaction with these services. 
 Assess compliance with pharmacologic treatment, patient’s concerns about side effects, and satisfaction with the symptom relief..  
 If compliance is poor, assess and construct a plan to circumvent obstacles to compliance, or discuss alternative interventions that present fewer obstacles.  
 After 8 weeks of treatment, if symptom reduction and satisfaction with treatment are poor, despite good compliance, alter the treatment course (e.g., add a 
psychological or pharmacological intervention; change the specific medication; refer to individual psychotherapy if group therapy has not proved helpful). 
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Screening and Assessment – Anxiety in Adults with Cancer 
*In this algorithm the use of the word anxiety refers to the GAD-7 scale and not to a clinical diagnosis of anxiety disorder(s).  
 
1. Initial diagnosis/start of treatment, regular intervals during treatment, 3, 6, and 12 months post treatment, diagnosis of at recurrence or progression, when approaching death 
and during times of personal transition or re-appraisal such as family crisis (CAPO guideline: “Assessment of Psychosocial Health Care Needs of the Adult Cancer Patient” by 
Howell et al, 2009; Cancer Care Nova Scotia Distress Management Pathways, draft 2010). 
2. Presence of symptom in the last two weeks, rated as follows: 0 = not at all, 1 = several days, 2 = more than half the days, and 3 = nearly every day.  Content of items:  feeling 
nervous, anxious, on edge; cannot stop/control worry; worry too much; trouble relaxing; restlessness; easily annoyed, irritable; and, feeling afraid.  Final item regarding 
difficulty of the problems  
Note:  Reference for GAD-7 cutoffs is Spitzer, R.L. et al.  (2006).   A brief measure for assessing generalized anxiety disorder.  Arch Intern. Med.  
None/Mild Symptomatology 
If patient reports a total 
Score of 0-4, 5-9 
 
Moderate Symptomatology 
If patient reports a total 
Score of 10-14 
 
Moderate Severe to Severe 
Symptomatology If patient 
reports a total Score of 15-21 
 
Moderate Severe to 
Severe Symptomatology  




If at any time there is risk of harm to self and/or to others: 
If YES > Referral for emergency evaluation; Facilitate safe environment; One-to-one observation; Initiate interventions to 
reduce risk of harm to self and/or others. (The presence of other symptoms, e.g., psychosis, severe agitation and confusion 
(delirium), may also warrant emergency evaluation).    
If NO > Continue with algorithm  
 
 May present as worries or concerns 
re: cancer but also multiple other 
areas 
 Fatigue, sleep disturbances, 
irritability, and concentration 
difficulties may also be present 
 Functional impairment from ‘mild’ 
 Consider possible comorbid 
symptoms such as panic and/or 
social phobia 
Identify pertinent history / specific risk factors for (generalized) anxiety  
 History:  Familial history of anxiety, w/wo prior treatment 
 History:  Persons with other comorbid psychiatric disorders (e.g., mood disorders) 
 History of alcohol use or abuse  
 Presence of alcohol use or abuse 






 None or mild symptoms of 
anxiety 
 No/minimal functional 
impairment  
 Effective coping skills and access 
to social support 
 Written materials as appropriate 
 
 Symptoms interfere moderately to 
markedly with functioning, or  
 Symptoms not responding to 
Pathway 2  
 Referral to psychology and/or 
psychiatry for diagnosis and 
treatment 
 Consider possible comorbid 
diagnoses such as panic disorder 
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Care Map – Generalized Anxiety  in Adults with Cancer 
 Offer referral to supportive care 
services  
 
Intervention Options (low intensity) 
 Education and active monitoring 
 Non facilitated or guided self-help (or 
computerized) based on cognitive behavior 
therapy (CBT; including behavioral 
activation and problem solving)  
 Psychosocial interventions (group) 
 Pharmacologic, as appropriate 
 
Intervention Options (high intensity) 
 Psychological (individual: CBT or 
applied relaxation) 




 Delivered by licensed mental health professionals using relevant treatment manuals which may include some or all of 
the following content:  cognitive change, behavioral activation, biobehavioral strategies, education, and/or relaxation 
strategies.   
 Relapse prevention additions are also important as GAD is most often chronic.   
 Monitor for efficacy.    
 
Supportive Care Services for All Patients, As Available and Appropriate 
Provide education and information (verbal plus any relevant materials) for the patient and family about: 
 Normalcy of stress and anxiety in the context of cancer  
 Specific stress reduction strategies (e.g., progressive muscle relaxation) 
 Sources of informational support/resources (patient library, reliable internet sites)  
 Availability of supportive care services (e.g., professionally led groups, informational lectures, volunteer organizations) for the 
patient and family at the institution or in the community  
 Availability of financial support (e.g., accommodations, transportation, health/drug benefits) 
 Information about signs and symptoms of anxiety disorders and their treatment 
 Information on sleep hygiene and self-management of fatigue  




 SSRIs or anxiolytics with choice informed by side effect profiles, interactions, response, patient age and preference. 
 Consider interventions with short term duration.   
 Monitor regularly for adherence, side effects, and adverse events. 
 
Psychosocial (group) 
 Structured, professionally led, with topics such as:  stress reduction, positive coping (seeking information, problem 
solving, assertive communication), enhancing social support from friends/family, coping with physical symptoms (e.g., 
fatigue, sexual dysfunction) and bodily changes. 




Care Pathway 1 




Care Pathway 2 
Psychological (group) or Psychosocial 
 
Moderate Severe to Severe Symptoms  
 
Care Pathway 3 
 
Psychological (individual) and/or Psychiatric 
 
Follow-up and ongoing re-assessment  
As cautiousness and a tendency to avoid threatening stimuli are cardinal features of anxiety pathology, it is common for persons with symptoms of anxiety to 
not to follow through on potentially helpful referrals or treatment recommendations. With this in mind, on a monthly basis or until symptoms have subsided: 
 Assess follow-through and compliance with individual or group psychological/ psychosocial referrals, as well as satisfaction with these services. 
 Assess compliance with pharmacologic treatment, patient’s concerns about side effects, and satisfaction with symptom relief.   
 Consider tapering the patient from any antidepressant medications if anxiety symptoms are under control and if the primary environmental sources of 
anxiety are no longer present. 
 If compliance is poor, assess and construct a plan to circumvent obstacles to compliance, or discuss alternative interventions that present fewer obstacles.  
o After 8 weeks of treatment, if symptom reduction and satisfaction with treatment are poor, despite good compliance, alter the treatment course 
(e.g., add a psychological or pharmacological intervention; change the specific medication; refer to individual psychotherapy if group therapy has 
not proved helpful). 
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Screening and Assessment – Fatigue in Cancer Survivors 
History and Physical  
1) Perform a focused fatigue history, including:  
• Onset, pattern, duration 
• Change over time 
• Associated or alleviating factors  
 
2) Evaluate disease status by: 
• Evaluate risk of recurrence based on stage, pathologic factors, and treatment history  
• Perform review of systems to determine if other symptoms substantiate suspicion for recurrence  
 
3) Assess treatable contributing factors: 
• Comorbidities (e.g, cardiac dysfunction, endocrine dysfunction, pulmonary dysfunction, renal dysfunction, 
anemia, arthritis, neuromuscular complications, sleep disturbances, pain, emotional distress)  
• Medications (consider persistent use of sleep aids, pain medications, or antiemetics)     
• Alcohol/substance abuse  
• Nutritional Issues 
• Weight/caloric intake changes  
• Deconditioning  
 
As a shared responsibility, the clinical team must decide when referral to an appropriately trained professional (e.g., 
cardiologist, endocrinologist, mental health professional, internist, etc.) is needed. 
   
Laboratory Evaluation  
• Consider performing laboratory evaluation based on presence of other symptoms, onset, and severity of fatigue  
• CBC with differential  
o Compare end-of-treatment hemoglobin/hematocrit with current values  
o Assess other cell lines (WBC and platelets)  
• Comprehensive metabolic panel  
o Assess electrolytes  
o Assess hepatic and renal function  
• Endocrinologic evaluation 
o TSH  
o Consider more comprehensive evaluation or referral to specialist if other symptoms present  
 
   
   
Use a numeric rating scale as clinically indicated and at least annually. 
 
 
            









Routinely screen for fatigue  
Comprehensive and Focused Assessment  
(for patients who report moderate to severe fatigue) 
• All patients should be offered specific education about fatigue following treatment (e.g. information about the 
difference between normal and cancer related fatigue, persistence of fatigue post treatment, and causes and 
contributing factors).All patients should be offered advice on general strategies that help manage fatigue (e.g., 
maintaining physical activity) and guidance on self-monitoring of fatigue levels. 
Education and Counseling   
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Treatment and Care Map – Fatigue in Cancer Survivors 
• Initiating/maintaining adequate levels of physical activity can reduce cancer-related fatigue in post-treatment survivors.  
• Actively encourage all patients to engage in a moderate level of physical activity after cancer treatment (e.g., 150 minutes of 
moderate aerobic exercise (such as fast walking, cycling, or swimming) per week with an additional 2 to 3 strength training  
(such as weight lifting) sessions per week, unless contraindicated.   
• Walking programs are generally safe for most cancer survivors; the American College of Sports Medicine recommends that 
cancer survivors can begin this type of program after consulting with their doctors, but without any formal exercise testing (such 
as a stress test). 
• Survivors at higher risk of injury (e.g., those living with neuropathy, cardiomyopathy, or other long-term effects of therapy other 
than comorbidities) should be referred to a physical therapist of exercise specialist. Breast cancer survivors with lymphedema 
should also consider meeting with an exercise specialist before initiating upper body strength-training exercise.  
Adapted from "A pan-Canadian practice guideline and algorithm: screening, assessment and supportive care of adults with cancer-
related fatigue by D. Howell et al., Current Oncology, 20(3), p. e242-e243. Copyright 2003 by Current Oncology. Adapted with 
permission. 
 
• There is some evidence that the following interventions can reduce fatigue in cancer survivors:  
o Mindfulness-based approaches  
o Yoga   
o Acupuncture  
 
• The following interventions may offer some benefit, however additional research, particularly in the post-treatment population, is 
needed:   





Address all medical and substance-induced treatable contributing factors first (e.g., pain, depression, anxiety, emotional 
distress, sleep disturbance, nutrition deficit, activity level, anemia, medication side-effects, and comorbidities). See Table 2 for 










• Cognitive behavioral therapy/behavioral therapy can reduce fatigue in cancer survivors. 
• Psycho-educational therapies/educational therapies can reduce fatigue in cancer survivors. 
• Survivors should be referred to psychosocial service providers who specialize in cancer and are trained to deliver empirically-
based interventions.  Psychosocial resources that address fatigue may also be available through the National Cancer Institute 
(e.g., Moving Beyond Breast Cancer videos).   
 
Mind-Body Interventions 
Pharmacologic Interventions  
• Evidence suggests that psychostimulants (e.g., methylphenidate) and other wakefulness agents, eg., modafinil can be 
effectively used to manage fatigue in patients with advanced disease or those on active treatment.  However, there is very 
limited evidence of their effectiveness in reducing fatigue in patients who are disease free following active treatment, outside of 
the treatment of obstructive sleep apnea.   
• Small pilot studies have evaluated the impact of supplements, such as ginseng and vitamin D, for cancer-related fatigue. 
However, there is no consistent evidence of their effectiveness.    
Ongoing Monitoring and Follow-up  
Promote ongoing self-monitoring of fatigue levels as a late or long-term cancer or treatment problem in post-treatment survivors. 
  
Some patients may also benefit from interventions described below to treat fatigue.  Currently, there are no clear standards to 
select among these for an individual patient.  Further research is needed to establish a strategy for prioritizing, sequencing, and 
linking the available options. If treated for fatigue, patients should be followed and re-evaluated on a regular basis to determine 
whether treatment is effective or needs to be reassessed. 
 
Treat Contributing Factors 
Interventions for Cancer-Related Fatigue 
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PREVENTION AND MANAGEMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN SURVIVORS OF ADULT CANCERS: AMERICAN 
SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINE 
Clinical Question Recommendation Evidence Rating 
What are the optimum prevention 
approaches in the management of 
chemotherapy-induced neuropathies in  




There are no established agents recommended 
for the prevention of CIPN in cancer patients 
undergoing treatment with neurotoxic agents.   
This is based on the paucity of high-quality, 
consistent evidence and a balance of benefits 
versus harms. 
Type: Evidence-based 
Harms outweigh benefits 
Evidence quality:  Ranges from low to high 
Strength of Recommendation: Ranges from 
inconclusive to strong against 
 
 
Clinicians should not offer the following agents 
for the prevention of CIPN to cancer patients 
undergoing treatment with neurotoxic agents:  
• acetyl-L-carnitine (ALC)  
• amifostine  
• amitriptyline 
• CaMg for patients receiving oxaliplatin-
based chemotherapy  
• diethyldithio-carbamate (DDTC) 
• glutathione (GSH) for patients receiving 
paclitaxel/carboplatin chemotherapy 
• nimodipine  
• Org 2766 
• all-trans retinoic acid 
• rhuLIF 
• vitamin E  
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PREVENTION AND MANAGEMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN SURVIVORS OF ADULT CANCERS: AMERICAN 
SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINE 
Clinical Question Recommendation Evidence Rating 
Continued, 
What are the optimum prevention 
approaches in the management of 
chemotherapy-induced neuropathies in  
adult cancer survivors?  
 
 
Venlafaxine is not recommended for routine use 
in clinical practice.  While the venlafaxine data 
supports its potential utility, the data were not 
strong enough to recommend its use in clinical 
practice, until additional supporting data become 
available. 
 
Type:  Evidence-based 
Balance of benefits and harms 
Evidence quality: Intermediate 
Strength of Recommendation: Inconclusive 
 
 
No recommendations can be made on the use of 
N-acetylcysteine, carbamazepine, glutamate, 
glutathione for patients receiving cisplatin or 
oxaliplatin-based chemotherapy, goshajinkigan 
(GJG), omega-3 fatty acids, or oxycarbazepine for 
the prevention of CIPN at this time. 
 
Type: Evidence-based 
Balance of benefits and harms 
Evidence quality:  Low 
Strength of recommendation: Inconclusive 
 
What are the optimum treatment approaches 
in the management of chemotherapy-




For cancer patients experiencing CIPN, clinicians 
may offer duloxetine. 
Type: Evidence-based 
Benefits outweigh harms 
Evidence quality: Intermediate 
Strength of Recommendation: Moderate  
No recommendations can be made on the use of 
acetyl-L-carnitine, noting that a positive phase III 
abstract supported its value, but this work has not 
yet been published in a peer-reviewed journal 
and a prevention trial suggested that this agent 
was associated with worse outcomes. 
Type: Evidence-based 
Harms outweigh benefits 
Evidence quality:  Low 
Strength of Recommendation: Inconclusive 
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Continued, 
What are the optimum treatment approaches 
in the management of chemotherapy-






No recommendations can be made on the use of 
tricyclic antidepressants.  However, based on the 
limited options that are available for this 
prominent clinical problem and the demonstrated 
efficacy of these drugs for other neuropathic pain 
conditions, it is reasonable to try a tricyclic 
antidepressant (e.g., nortriptyline or desipramine) 
in patients suffering from CIPN following a 
discussion with the patients about the limited 
scientific evidence for CIPN, potential harms, 
benefits, cost, and patient preferences.   
Type: Evidence-based 
Balance of benefits and harms 
Evidence quality: Intermediate 
Strength of Recommendation: Inconclusive 
No recommendations can be made on the use of 
gabapentin, noting that the available data were 
limited regarding its efficacy for treating CIPN. 
However, the panel felt that this agent is 
reasonable to try for selected patients with CIPN 
pain given that only a single negative randomized 
trial for this agent was completed, given the 
established efficacy of gabapentin and pregabalin 
for other forms of neuropathic pain, and given 
the limited CIPN treatment options.  Patients 
should be informed about the limited scientific 
evidence for CIPN, potential harms, benefits, and 
costs.    
 
Type: Evidence-based 
Balance of benefits and harms 
Evidence quality: Intermediate 
Strength of Recommendation: Inconclusive 
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No recommendations can be made on the use of 
a topical gel treatment containing baclofen (10 
mg), amitriptyline HCL (40 mg), and ketamine (20 
mg), noting that a single trial supported that this 
product did decrease CIPN symptoms.  Given the 
available data, the panel felt that this agent is 
reasonable to try for selected patients with CIPN 
pain.  Patients should be informed about the 
limited scientific evidence for the treatment of 
CIPN, potential harms, benefits, and costs. 
Type: Evidence-based 
Benefits outweigh harms 
Evidence quality: Intermediate 
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